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Aims: The primary aim of this thesis was to explore the role of palliative 
radiotherapy in the treatment of pain in malignant pleural mesothelioma (MPM). 
The effect of radiotherapy on other symptoms was also examined. Biomarkers 
which might predict response to radiotherapy (Quantitative Sensory Testing – 
QST) were explored and objective evidence of response was sought via 
interpretation of Computed Tomography (CT) scans. The thesis also examined 
the  role of Positron Emission Tomography (PET)-CT in radiotherapy planning 
and characterising pain in MPM.  
Methods: A narrative review of the challenges of pain management in MPM and 
a systematic review of the evidence supporting the use of palliative radiotherapy 
for pain control in MPM, were undertaken. In addition, a multi-centre, single arm 
phase II trial was conducted which examined the role of radiotherapy in pain 
control in MPM. This trial also  assessed the role of PET-CT in radiotherapy 
planning and allowed for a characterisation of MPM-related pain. These 
components form the basis of this thesis. 
Results:  Palliative radiotherapy at a dose of 20 Gy in five daily fractions using 6 
Megavoltage (MV) photons improves pain in a significant proportion of patients 
with MPM. It does not have a beneficial effect on other symptoms or on quality 
of life. QST does not appear to be a useful clinical biomarker indicating 
likelihood of response to radiotherapy. Objective evidence of response via CT is 
low. Incorporation of PET-CT in the radiotherapy planning process alters the 
anatomical location of the target volume in patients with MPM. There is also an 
association between the Standard Uptake Value (SUV) uptake and pain, with the 
areas with highest SUV uptake being associated with the areas of pain. PET-CT 
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results in upstaging of a significant proportion of patients. Pain is often severe 
and debilitating for patients with MPM and it has often a combination of 
neuropathic and nociceptive mechanisms.  The presence of a neuropathic 
component to the pain is not associated with an increased likelihood of response 
to radiotherapy. 
Conclusions: Radiotherapy is effective at relieving pain in a proportion of 
patients with MPM and should be considered for all patients with MPM-related 
pain. PET-CT improves multiple parameters in the radiotherapy planning process 
compared with CT alone. QST parameters have not been shown to predict those 
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Chapter 1. Introduction  
1.1. Overview 
The French pathologist, Joseph Lieutaud, is credited with first describing a 
possible chest wall (pleural) tumour in 1767.[1] For many years however, 
tumours of the pleura were considered to be secondary tumours, as it was felt 
that primary tumours could not arise there. By the start of the twentieth century, 
opinion had changed and it was accepted that primary pleural tumours were an 
entity. The term mesothelioma was first used in 1909 by J. G. Amani,[1] with the 
first possible link between asbestos exposure and mesothelioma being made by 
the pathologist Steven Gloyne in 1935.[2] 
 
A seminal study which supported the link between asbestos exposure and 
mesothelioma was published in 1960.[3] This study examined 33 South Africans 
who were either miners or lived near a mine where crocidolite asbestos was 
harvested. The study had two main findings; firstly, exposure to asbestos was 
associated with the development of malignant pleural mesothelioma (MPM) and, 
secondly, the average period between exposure and developing MPM was 40 
years. Since then it has been accepted that asbestos exposure and the 
development of MPM, are linked.  
 
Asbestos refers to a group of naturally occurring fibrous minerals found in rock 
and soil. It has been used in the construction industry for centuries due to its 
desirable properties including resistance to fire, chemical or electrical damage, 
tensile strength and its relatively inexpensive cost. It has been used commonly 
for electrical and building insulation and also in ship building.  
 




There are two categories of asbestos; serpentine (chrysotile) and amphibole 
(crocidolite, tremolite, anthophyllite, amosite and actinolite). Chryosite - “white 
asbestos”, crocidolite - “blue asbestos” and amosite - “brown asbestos” are the 
three most commonly used forms of asbestos. Due to health concerns, the use of 
asbestos has been banned in the UK since 2009. If asbestos fibres remain intact, 
they pose little risk to health. However when the fibres are damaged, released 
into the air and subsequently inhaled, then they can be detrimental to health. 
 
Exposure to asbestos fibres can have various effects. It may cause pleural 
plaques, asbestosis, lung cancer or MPM.  
Pleural plaques are areas of scar tissue on the pleura (lining of the lung). They 
may be seen on X-ray or CT imaging and indicate that the individual has been 
exposed to asbestos. They are not pre-malignant and usually do not cause 
symptoms. 
Asbestosis is an interstitial pneumonitis and fibrosis caused by deposition of 
asbestos fibres within the lung. The risk of developing asbestosis increases with 
cumulative exposure and with time since initial exposure. Treatment is 
symptomatic.[4]     
Lung cancer may also be caused by exposure to asbestos. Smoking and asbestos 
exposure are the two most common risk factors for lung cancer with 9-15% of 
cases attributed to asbestos.[5] Smoking and asbestos exposure are synergistic in 
terms of their risk of developing lung cancer.[6] The connection between 
asbestosis and lung cancer is not currently clear. Asbestosis is associated with 
significant exposure to asbestos and so may signify an increased risk of cancer. 
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Alternatively, the inflammation associated with asbestosis may trigger 
carcinogenesis. 
The malignancy most commonly associated with asbestos exposure is MPM, 
which will be discussed further.  
 
1.2. Epidemiology  
The majority of cases of MPM are associated with asbestos exposure. However, 
in some patients, there may be no obvious exposure to asbestos. Other 
carcinogens known to cause MPM include radiation, exposure to the simian virus 
40 and the mineral fibre erionite.[7] The latency period between exposure and 
the development of MPM may be in the region of 30-40 years. In 2010, over 
2500 people were diagnosed with MPM in the UK with a male:female ratio of 
approximately 5:1 (total new cancer diagnoses in the UK for 2010 were 
324,579).  Over 2000 people in the UK died of MPM that same year.[8] The UK 
standard mortality rate for MPM is shown in Figure 1. 
 




Figure 1 - UK Standard Mortality Rate for MPM[9] 
 
It is thought that the incidence of MPM has already peaked in the USA. 
However, in other countries such as China, Russia, Brazil and India, asbestos 
continues to be produced. Due to this, exposure to asbestos is still on the rise in 
these countries and it is thought that the incidence of MPM is yet to peak in these 
countries. Predicting the level of increased incidence in these countries is 
extremely difficult. [1] Several countries do not keep accurate records of MPM 
incidence however it is known that Australia has the second highest mortality 
rates in the world, second only to the UK. Asbestos was extensively used in 
Australia from the 1950’s to the 1970’s. In 2007, 551 Australians died from 
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The natural history of MPM incidence is still unknown. It is estimated that 
exposure to asbestos in the UK peaked in 1963 and therefore, due to the latency 
period, it is anticipated that mortality will peak in 2016 and decline rapidly after 
that. Although the worldwide incidence of MPM is not known, it is generally 
accepted that the rates in Great Britain are among the highest in the world.[8] 
Given the long latency period, it is not surprising that 80% of patients diagnosed 
with MPM are over the age of 65.[8] Therefore, MPM primarily affects an 
elderly population and remains a public health issue today. 
 
1.3. Pathophysiology  
MPM is a tumour which originates in pleural lining of the lung. In this lining 
there is a membrane called the mesothelium which is also present in other body 
cavities, however the reason for development of mesothelioma in the pleura is 
likely to be due to direct contact between this lining and asbestos fibres.   
 
Much progress has been made in recent years in our understanding of the 
pathophysiology of MPM. (See Figure 2.) However, exactly how exposure 
causes MPM is not fully understood. It has been shown that, following inhalation 
of asbestos fibres, an acute inflammatory reaction can be seen with inflammatory 
cytokines, macrophages and neutrophils present in large numbers. These 
inflammatory changes are followed by mesothelial cell proliferation.[10] The 
activated inflammasone, a component of macrophages or mesothelial cells that 
leads to the production of angiogenic, growth-promoting and chemotactic 
cytokines, is felt to play a role in the ongoing inflammation.[11] Furthermore, a 
number of defects in the molecular signalling pathways and disruption of cell 
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cycle control are seen in MPM.[11] In addition, it is known that in 40-50% of 
mesotheliomas, the tumour suppressor gene, Neurofibromatosis Type 2 (NF2), is 
inactivated.[12] This tumour suppressor gene negatively regulates the cyclin D1 
regulatory axis. It is also known that tumour necrosis factor-alpha and nuclear 




Figure 2 - Pathophysiology of MPM[11] 
Reproduced by kind permission of Dr. Brooke Mossman 
 
1.4. Symptoms of MPM 
Most patients are symptomatic at the time of diagnosis of MPM. The most 
common symptoms are chest pain and breathlessness, occurring in 25-90% and 
34-46% of patients respectively.[14-16] Patients also commonly suffer from 
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lethargy, cough and sweating.[16] Pain, the most common symptom, is discussed 
extensively in chapter 2. 
 
1.5. Diagnosis of MPM 
Typically, the first investigation performed in patients suspected of having MPM, 
is a chest x-ray. This may show pleural thickening or a pleural effusion, as seen 
in Figure 3. These findings can be suggestive of MPM but are not diagnostic.  
 
Figure 3 - Chest X-ray showing typical features of MPM with pleural 
thickening  as indicated by the arrows. X-ray taken from national archive 
from a patient in the SYSTEMS study 
 
The next investigation is usually a CT scan which gives a more detailed image of 
the chest and abdomen and can provide further weight to support a diagnosis of 
MPM, as shown in Figure 4.  
 




Figure 4 - Axial CT image showing MPM encasing the right lung and 
invading through right anterior chest wall as indicated by the arrow. CT 
taken from national archive from a patient in the SYSTEMS study 
 
However, pathological confirmation through histology remains the cornerstone 
of diagnosis of MPM, though reliable diagnosis remains difficult in some cases, 
especially if biopsy samples are small. Biopsies may be obtained via 
thoracoscopy - Figure 5.  
 
 




Figure 5 - Thoracoscopy 
Reproduced with the kind permission of Dr. K. Blyth. Unpublished slide 
from Dr. Blyth’s personal collection 
 
Neoplastic invasion is generally regarded as the key factor in diagnosing MPM 
as opposed to reactive mesothelial hyperplasia.[17, 18] Key histological features 
can be seen in Figure 6 and Figure 7. 
 
Unfortunately, sometimes the biopsy can be inconclusive or the patient may not 
be fit enough to consider a biopsy. In these situations, a clinical diagnosis of 
MPM may be made if there is radiological evidence strongly suggestive of MPM 
in a patient with a known history of asbestos exposure. In such circumstances, a 
post mortem must be performed since MPM is an occupational disease and must 
be discussed with the Procurator Fiscal (coroner) in Scotland.  Although 
histological diagnosis remains the gold standard for diagnosing MPM, there is 
some evidence suggesting that proteomics may be an alternative option in 
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diagnosing MPM. A study of 117 patients with a histological diagnosis of MPM 
and 142 individuals with a history of asbestos exposure but no diagnosis of 
MPM, analysis of serum was conducted.[19] As a result, a 13-biomarker panel 
was discovered which detected MPM with an accuracy of 92%. This biomarker 
panel may be helpful in detecting early stage disease given 88% were detected at 
stage I and II. 
 
 
Figure 6 – Histological Features (1) 
Positive calretinin staining giving the diagnosis of epithelioid mesothelioma as 
indicated by the arrow 
Reproduced with the kind permission of Dr. C. Dick from his personal 
collection. Unpublished slide. 
 




Figure 7 –  Histological Features (2) 
Hematoxylin and eosin staining showing the mesothelioma cells at high power as 
indicated by the arrow. 
Reproduced with the kind permission of Dr. C. Dick from his personal 
collection. Unpublished slide. 
 
There are three main histological subtypes of MPM. The most common is 
epithelioid accounting for approximately 50% of cases; sarcomatoid accounts for 
16% and there is a mixed histological pattern in the remainder of cases.[20] It is 
well recognised that epithelioid histology is associated with the best 
prognosis.[21, 22]  
 
1.6. Treatment of MPM 
There is still much debate as to the optimal management of MPM. In broad 
terms, the treatment options include surgery, chemotherapy, radiotherapy and 
best supportive care. As with all cancers, the performance status of the patient is 
key in deciding the optimal treatment to offer the patient. The Eastern 
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Cooperative Oncology Group (ECOG) scale is the most commonly used measure 
to assess performance status, in clinical practice.[23] 
 
1.6.1. Surgery  
For patients with good performance status who have disease limited to the chest, 
the main debate is whether they should be considered for radical surgery, 
traditionally extra pleural pneumonectomy (EPP), followed by chemotherapy and 
radiotherapy in a tri-modality approach. The Mesothelioma And Radical Surgery 
(MARS) study showed that EPP patients had a poorer survival than those who 
did not undergo EPP.[24] Due to this study, this option has fallen out of favour in 
the UK.[24] However, some in the international community refute the 
conclusions of the MARS study and so EPP is still offered in certain parts of the 
world.[25] Therefore, there is a divide between the UK and the rest of the world 
in terms of the surgical management of MPM patients. Given the significant 
morbidity and mortality associated with EPP surgery, there has been a trend 
towards performing pleurectomy/decortication for certain patients with 
MPM.[26]  
 
1.6.2. Chemotherapy  
Two phase III studies have shown a survival advantage for platinum/antifolate 
combination chemotherapy. The first of these studies randomised patients 
between single agent cisplatin and cisplatin in combination with pemetrexed. 
Median survival was 9.3 months for cisplatin and 12.1 months for the 
combination arm.[27] The second study compared cisplatin with cisplatin and 
raltitrexed and achieved a survival advantage of 2.6 months for the 
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cisplatin/raltitrexed arm.[28] In view of these results, the British Thoracic 
Society (BTS) recommends that all patients with MPM who have a performance 
status of 0-2 should be given the opportunity to discuss the merits of 
chemotherapy. It is worth noting, however, that in another study of 146 patients 
diagnosed with MPM, only 54 were considered fit for consideration of 
chemotherapy. Of these, only 26 underwent chemotherapy, so this treatment may 
not be suitable for the majority of patients diagnosed with MPM.[29]  
 
1.6.3. Radiotherapy  
Radiotherapy may be given in three broad areas in MPM:  
As part of tri-modality therapy in the radical setting  
 At drain sites to try to prevent drain site metastases  
In the palliative setting to help with symptom control  
As already discussed, tri-modality therapy is not currently offered in the UK and 
there are no randomised data to support its use. The role of prophylactic drain 
site irradiation is the subject of two current UK-wide studies, SMART and PIT, 
the results of which are eagerly awaited.[30, 31] 
 
Radiotherapy may be offered to help palliate some of the symptoms of MPM.[32, 
33] By far the most common use in this setting is in the palliation of pain. 
However, there is limited evidence to support the use of radiotherapy in this 
situation and further work in this area is needed.[34] For example, the optimal 
dose and fractionation that should be used is not known since there are no 
randomised trials examining this.  
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The optimal method with which to assess response to radiotherapy in MPM is 
not known. While CT scanning is commonly used in many situations in 
Oncology, such as initial staging and assessing response to chemotherapy, it is 
not commonly performed to assess response to palliative radiotherapy. However, 
a recent study which evaluated the role of palliative radiotherapy in MPM 
performed CT scans two months after radiotherapy and quoted a 43% response 
rate along with a clinical response rate at two weeks of 57%.[35] This was the 
first study in MPM to show a radiological response to radiotherapy. However, 
the authors did not state whether those who responded radiologically, also 
responded clinically. Therefore, the association between clinical and radiological 
response is unknown and warrants further investigation. 
 
Defining the target volume in MPM is difficult since the disease spreads 
diffusely across the pleural surface and delivering palliative radiotherapy to a 
large area is potentially very toxic. Therefore, when palliative radiotherapy is 
given, the clinician is left with the challenge of treating effectively whilst 
balancing the risks of toxicity, in a treatment with palliative intent.  
 
[F-18]-fluoro-deoxy-glucose (FDG) positron emission tomography computerized 
tomography (PET-CT) has become established as an essential imaging modality 
in many tumour types such as non-small cell lung cancer, lymphoma and 
oesophageal cancer.[36-38] It is beginning to be used in several settings in MPM. 
Studies have demonstrated the usefulness of FDG PET-CT in pre-operative 
imaging, differentiating benign from malignant disease, evaluation of response to 
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chemotherapy and in prognostication based on the intensity of FDG uptake in 
MPM.[39] 
 
There is, however, emerging evidence that PET-CT may be of use in 
radiotherapy planning in MPM. Pehlivan and co-workers have conducted 
preliminary work examining the role of PET-CT in radiotherapy planning in 
MPM.[40] In comparison with CT, they demonstrated that incorporating PET-
CT into radiotherapy planning resulted in significant reductions in Gross Tumour 
Volume (GTV), Clinical Target Volume (CTV) and Planning Target Volume 
(PTV). With these reductions in target volumes, the authors hypothesized that 
dose escalation of radiotherapy to previously unachievable levels may now be 
possible. However, lack of intensity modulated radiotherapy (IMRT) in this work 
meant that developing sophisticated plans to deliver radical or high palliative 
doses to these patients, was not possible. Therefore, the role of FDG PET-CT in 
radiotherapy planning in MPM warrants further investigation. 
 
1.7. Prognosis in MPM 
Unfortunately, prognosis in MPM remains poor. Over a 10 year period from 
1984 to 1993, 204 patients were entered into five European Organisation for the 
Research and Treatment of Cancer (EORTC) phase II studies.[41-44] The 
median survival was 12.6 months from diagnosis and 8.4 months from study 
entry.[45] Other studies quote median survival figures of a year or less.[16, 46, 
47] Single institution studies of tri-modality therapy quote median survival 
figures of up to five years for node negative tumours.[48] While prognosis is 
poor in MPM, it has been suggested that certain factors can divide patients into 
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good and poor prognostic groups.[45] Poor performance status, a high white cell 
count, male gender, uncertainty regarding histological diagnosis and sarcomatoid 
subtype were all identified as poor prognostic factors based on the survival of 
204 patients entered into the EORTC studies.[41-44] Taking these into account, 
if patients had more than two of these factors, they were classified as poor 
prognosis with a 1 year survival of 12%. Those with two or fewer factors had a 1 
year survival of 40%.  
 
 
1.8. Thesis Overview 
This thesis examines mesothelioma with a key focus on the role of radiotherapy 
for pain control in MPM. It is largely informed by the SYSTEMS study which 

















of Pain in MPM SYSTEMS 
study
 
Figure 8 - Thesis overview  
 




1.9. Aims of this Thesis 
The overall aim of the thesis is to examine key aspects of radiotherapy in MPM.    
These are detailed as follows:- 
To undertake a critical review of pain management in MPM. 
To undertake a systematic review of the literature examining the current 
evidence for radiotherapy in the relief of pain in MPM. 
To establish whether radiotherapy is beneficial in treating pain in MPM.  
To assess whether radiotherapy affects other key symptoms such as 
breathlessness, fatigue and distress, using validated questionnaires. 
To examine the effect of radiotherapy on tumour bulk, using CT scanning. 
To assess the toxicity of radiotherapy. 
To examine possible biomarkers of radiotherapy response.  
To assess the role of PET-CT scanning in radiotherapy planning. 
To characterise pain in MPM. 
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Chapter 2. Pain Management in Mesothelioma 
2.1. Introduction 
Cancer pain can be divided into acute and chronic pain syndromes.[49] Acute 
cancer pain is usually caused by a definable acute illness.[49] It has a definite 
onset and its duration is predictable and limited. Chronic cancer pain is 
differentiated from acute pain by its longevity and is regarded as pain lasting 
more than 12 hours a day. Approximately 75% of all cancer patients suffer from 
chronic pain.[50]  
 
In MPM, pain usually affects the chest, in keeping with the underlying disease. 
However the cause of chest pain in MPM is multifactorial. Pain may be due to 
direct tumour infiltration of ribs, nerve roots, intercostal nerves, chest wall or, in 
some cases, due to the tumour invading the neurovascular bundle. In addition, in 
patients who undergo surgery, post thoracotomy pain is common.[51] The pain 
associated with MPM is often more severe and difficult to treat than pain caused 
by lung cancer.[52] 
 
 
The pathophysiology of pain in MPM is generally a combination of nociceptive 
and neuropathic pain, termed mixed pain. Therefore, managing this pain can be 
extremely difficult and multiple analgesics, which target different pain 
mechanisms, are often required. Unfortunately, patients may continue to suffer 
from severe pain despite multiple analgesics and so other options to consider for 
these patients include palliative radiotherapy, chemotherapy, neuraxial pain 
techniques, and cordotomy. All these therapeutic options will be discussed. 
 




The difficulties of pain management in MPM are perhaps best illustrated via a 
case history. 
 
2.2. Case history 
A 68-year-old man presented to his local hospital with severe right-sided chest 
pain and breathlessness. He had worked as an apprentice carpenter in the 
shipbuilding industry many years ago. A chest X-ray was performed which 
showed a right-sided pleural effusion and pleural thickening. A CT scan, Figure 
9, including a CT guided biopsy, was performed with pathology confirming 
MPM of sarcomatoid type. Treatment options were discussed with the patient. 
Chemotherapy was declined by the patient due to low likelihood of benefit. The 
patient agreed that treatment would be symptomatic only.  
 
The gentleman described his pain as “stabbing and shooting”, suggesting a 
neuropathic component. He also stated that it was severe in intensity. Prior to 
admission, he had been taking tramadol (400mg daily) and gabapentin (900mg 
daily). During his admission, he was commenced on 40mg of morphine sustained 
release tablets (every 12 hours), 15mg of immediate release morphine tablets 
when needed for pain, and a lidocaine patch applied over the chest wall. 








Figure 9 - CT scan - MPM invading chest wall as indicated by arrow. CT is 
from a patient in the SYSTEMS study and taken from the national archive  
 
Pain continued to be problematic and when his morphine dose was escalated, he 
developed signs of opioid toxicity (muscle jerks and pseudo-hallucinations).  He 
was therefore switched to oxycodone sustained release tablets (30mg twice 
daily). With this, his opioid toxicity improved, though was still present. His 
gabapentin was increased to 1800mg daily and he remained on a lidocaine patch. 
Despite all this, his pain remained poorly controlled. At this point, he received 
radiotherapy with the aim of improving his pain. Using 6MV photons, 20 Gy in 5 
daily fractions of radiotherapy were administered which brought about a 
temporary improvement in his pain but six weeks after treatment, his pain was as 
severe as it had been prior to his radiotherapy. Following this, he was considered 
for cordotomy but unfortunately died before he was able to receive this. 
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This case illustrates some of the difficulties patients with MPM face in terms of 
pain management. Despite multiple analgesics and palliative radiotherapy, his 
pain remained poorly controlled. The complex pathophysiology of pain in MPM 
combined with suboptimal analgesics means that achieving pain control can be 
difficult, though it should be noted that not all cases of MPM are as challenging 
as this.  
 
2.3. Principles of pain control in MPM 
Given that the pain associated with MPM is often multifactorial, patients are 
often on several drugs, which work via different mechanisms of action. Opioids 
are commonly used and its effects are mediated by specific opioid receptors both 
within the central nervous system and peripherally.[53] Adjuvant analgesics are 
commonly added if opioids are not controlling the pain adequately. 
Antidepressants are the most commonly used adjuvant analgesics. These drugs 
are thought to enhance availability of monoamines at synapses within neural 
pathways that are part of the descending pain modulation system. The most 
important modes of action include inhibition of norepinephrine reuptake and 
serotonergic and dopaminergic effects.[53] Anticonvulsants have also been used 
as adjuvant analgesics. Gabapentin and pregabalin act at the alpha-2-delta 
voltage gated subunit of the calcium channel in the dorsal horn.[53] 
 
 It is always important to weigh up the potential benefits of multiple analgesics 
against the possibility of cumulative toxicity, drug interactions and patient 
compliance.  The key components of analgesic treatment are detailed below. 
Commonly used medications and doses are detailed in Table 1. 
 





Table 1- Drugs and dose ranges commonly used for pain management in 
MPM 




Paracetamol Non Opioid 1g QDS 4g  
Diclofenac Non Opioid 50mg TDS 150mg  
Codeine Phosphate Weak Opioid 30-60mg QDS 240mg  












Gabapentin Adjuvant 300mg OD 3.6g 
Pregabalin Adjuvant 75mg BD 300mg  
Amitriptyline Adjuvant 10mg OD 150mg  
Lidocaine Adjuvant 5% patch 12 
hours on, 12 
hours off 
5% patch 12 
hours on, 12 hours 
off 
Fentanyl Strong Opioid 12mcg per hour. 




Ketamine Adjuvant 5mg BD No maximum 
 





Abbreviations: OD, once daily; BD, twice daily; TDS, three times daily; QDS, 
four times daily 
The World Health Organisation’s (WHO) Analgesic Ladder for Cancer Pain 
Relief is recognised as the gold standard for treatment of cancer pain,[54] Figure 
10, and its principles have been continued in new guidelines.[55, 56] It is easy to 
follow and can be applied to all types of pain, irrespective of aetiology. The first 
step on the ladder recommends using paracetamol or non-steroidal anti-
inflammatories. If pain remains poorly controlled then patients should move on 
to step two, which involves the use of weak opioids such as codeine. However, 
most patients with pain from MPM will  move quickly to step three of the ladder 
which recommends strong opioids plus or minus non-opioids or adjuvant 
analgesics. Therefore, step two may be skipped and a step three opioid used as 
the first line opioid.[55]  Morphine remains the most commonly used strong 
opioid, although there are now a multitude of others available and often patients 
may have to try several different strong opioids, in an attempt either to improve 
analgesic benefit/reduce side effects or both.[55]  
 




Figure 10- WHO Analgesic Ladder taken from www.who.int[54] 
 
2.3.1. Opioids 
Given the severity of pain associated with MPM, the majority of patients will 
require opioid analgesia, with morphine being the most commonly used. It comes 
in both immediate and sustained release preparations, which are equivalent in 
terms of analgesic benefit.[57, 58] Immediate release preparations are favoured 
by many for initial dose titration and subsequent breakthrough analgesia, while 
sustained release preparations are more typically saved for long term use.[59] 
However, a direct titration using sustained released opioids is equally 
feasible.[57] Patients may require large quantities of opioids to help control their 
pain. It is not uncommon, on these large doses, for patients to develop toxicity, 
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with symptoms such as somnolence, myoclonic jerks, cognitive impairment and 
hallucinations being prevalent. In these circumstances, most clinicians would 
favour a switch to another opioid such as oxycodone. 
 
2.3.2. Adjuvant Analgesics 
Adjuvant analgesics are drugs whose main indication is not analgesia but they 
have analgesic properties. Adjuvants are used in many types of pain including 
neuropathic pain. They can be used in combination with opioid analgesics or in 
isolation. In MPM, adjuvant analgesics are often used in combination with 
opioids.[60] Given that there appears to be a significant neuropathic component 
to the pain in MPM, it is not surprising that these drugs are commonly used in 




A Cochrane review summarised the evidence for the use of antidepressants in 
non-malignant neuropathic pain.[61] Tricyclic antidepressants are the most 
commonly used in neuropathic pain. Amitriptyline has a marginally greater 
analgesic effect compared to other tricyclic antidepressants such as nortriptyline. 
Selective Noradrenaline reuptake inhibitors (SNRI) such as duloxetine and 
venlafaxine may be of benefit in neuropathic pain, with duloxetine being 
favoured due to a better side effect profile.[62, 63]  
 
 




There is good evidence that anticonvulsants are effective in neuropathic pain.[64] 
Gabapentin has been used in the treatment of neuropathic pain for many years 
and is recommended as a first line treatment.[65] It is generally well tolerated 
although its dose limiting toxicity is usually somnolence. Pregabalin works in the 
same way as gabapentin and there is good evidence of its efficacy as an 
analgesic.[66-68] A recent prospective, placebo controlled, randomised 
controlled study compared pregabalin with gabapentin and amitriptyline for 
neuropathic cancer pain. The results suggested that all these drugs were effective 
in relieving cancer-related neuropathic pain but that pregabalin was associated 
with the greatest reduction in pain scores.[69] 
 
2.3.5. Ketamine 
There is some evidence supporting the benefit of ketamine in cancer pain.[70] If 
symptoms exist which are suggestive of central wind-up, such as pain on light 
touch or increased pain to any painful stimulus, then ketamine may be helpful. 
Furthermore, ketamine may renew opioid response when opioid doses are being 
increased with reduced response. 
 
2.3.6. Topical analgesics 
Topical analgesics can play a role in the treatment of pain in MPM, with topical 
5% lidocaine patches being the most commonly used. The main benefit of these 
patches is the lack of systemic side effects with local skin irritation being the 
common side effect. Though there have been no prospective studies in cancer 
patients, a retrospective review from Australia looked at 97 patients treated with 
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lidocaine 5% patches and the results supported its use in post herpetic, post-
surgical and cancer related neuropathic pain.[71] The high potency 8% capsaicin 
topical patch has proven efficacy in post herpetic neuralgia.[72] A single 
application of the patch for 30-60 minutes can result in pain relief for up to three 
months.  
 
2.4. Radiotherapy  
Many patients with MPM will continue to suffer from severe pain despite 
multiple analgesics, therefore, radiotherapy is often considered for these patients. 
However, there is a dearth of evidence to support its use in any setting in MPM. 
Despite this, radiotherapy for pain relief is recommended in guidelines from the 
European Respiratory Society in collaboration with the European Society of 
Thoracic Surgeons.[73] 
 
Perhaps the most convincing evidence in favour of radiotherapy to help pain 
comes from a study where 22 patients with MPM and pain were treated with 
hemi thoracic irradiation at a dose of 30 Gy in 10 daily fractions. Patients were 
treated with Cobalt-60 machines. Of the 19 patients assessable at three months, 
13 had an improvement in their pain scores, with no increase in their analgesic 
requirements, though the median duration of response was only two months.[33]  
 
A recent study looked at palliative radiotherapy at a dose of 36 Gy in 12 
fractions.[35] Radiotherapy was not given to the entire hemi-thorax but instead 
was directed to the area that was felt to be the source of the pain. The 
radiotherapy was given in this way because hemi-thoracic irradiation was felt to 
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be too toxic. The study showed that pain had improved in over 50% of patients 
two weeks after treatment. However, this was prospectively. Interestingly, CT 
scans were performed on these patients two months after radiotherapy and a 
response rate of 43% was reported, suggesting that, at an adequate dose, MPM 
may in fact be a radiosensitive disease.  
MPM has traditionally been regarded as a radioresistant disease and is felt to be 
intrinsically more radioresistant than the surrounding tissues.[74, 75] The only 
study to have looked at the radiosensitivity of MPM irradiated mesothelial cell 
lines with two Gray.[76] The alpha/beta ratio of the most sensitive cell lines were 
almost an order of magnitude greater than those of the two most resistant cell 
lines.[76] Given the lack of response to radiotherapy when given in 2 Gy per 
fraction[77] and the encouraging radiological response rate seen when a 
hypofractionated regime is given,[35] it could be that, MPM may be more 
radiosensitive than previously thought if a hypofractionated regime is chosen. 
   
The mechanisms by which radiotherapy reduces pain are not fully 
understood.[78, 79] An attempt was made to identify the mechanisms by which 
radiotherapy reduces bone pain in mouse models.[79] It was suggested that, with 
regard to bone pain, radiotherapy may help pain by reducing the cancer burden 
and by reducing osteolysis.  
 
2.5. Chemotherapy 
Several chemotherapeutic agents have been studied in this disease. Phase II trials 
have investigated the role of cisplatin, doxorubicin and gemcitabine but the 
results have been largely disappointing.[80-82] However, cisplatin has been 
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shown to be the most effective single agent and was used as the control arm in 
two phase III trials.[83] 
 
Vogelzang et al conducted a phase III study comparing cisplatin and pemetrexed 
in combination with cisplatin alone.[27] The study demonstrated a survival 
advantage for the combination regime with a median survival of 12.1 months 
versus 9.3 months for cisplatin alone. Median time to progression and response 
rates were also superior in the combination arm. Part way through the trial, folic 
acid and vitamin B12 were added. This significantly reduced toxicity in the 
combination arm. Similar survival results were seen in a phase II study where 
patients received carboplatin and pemetrexed suggesting that this combination 
could be an alternative treatment.[84] This regime was well tolerated with low 
rates of grade 3 and 4 neutropenia and anaemia.  
 
A second phase III trial compared cisplatin alone with cisplatin and 
raltitrexed.[28] The trial recruited 250 patients. Again, a survival advantage was 
seen for the cisplatin and antifolate arm with a median survival of 11.4 months 
versus 8.8 months for the cisplatin alone arm. The main toxicities were 
neutropenia and emesis which were twice as common in the combination arm. 
    
Quality of life data have been published from the raltitrexed/cisplatin phase III 
study.[85] These data showed that pain scores remained constant throughout 
treatment. The authors concluded that, in a disease with such a poor prognosis as 
MPM, stabilization of pain was a positive finding. However, the same data could 
also be interpreted as showing that chemotherapy does not improve pain control 
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in MPM. Therefore, chemotherapy should be prescribed in this disease in an 
attempt to improve survival rather than to improve pain. If symptom 
improvement is the aim, then other treatment options should be considered.  
 
Although chemotherapy can be offered, a retrospective review of MPM patients 
showed that, of 156 patients diagnosed, only 54 were deemed of adequate 
performance status to be offered chemotherapy, and ultimately only 27 patients 
received chemotherapy. Therefore, this treatment is not widely used in this 
population. [29]  
 
2.6. Epidural or intrathecal treatment (Neuraxial) 
Epidural or intrathecal treatments, usually with a combination of an opioid and a 
local anaesthetic, are alternative pain treatments for patients where other 
analgesics and radiotherapy fail to give pain relief.  Local anaesthetics lessen the 
need for opioids and thereby minimize opioid induced adverse effects. However, 
epidural or intrathecal pain therapies are invasive, are associated with a risk for 
infections, and require very close follow-up.[86]
 
 
Intra pleural analgesia, which involves administering local anaesthetics into the 
pleural space, has been described and felt to be effective for some 
malignancies.[87] However, no data exist for this procedure in patients with 
MPM and, therefore, stating a case recommending such a treatment in this 
patient group is difficult. 
 
 




Despite all of the above interventions, many patients with MPM continue to 
suffer from severe pain. In these instances, there may be a role for percutaneous 
cervical cordotomy (PCC). This procedure interrupts the spinothalamic tracts at 
the level of C1/2 and causes loss of pain sensation contralaterally. Unfortunately, 
there are no prospective, randomised data on the role of cordotomy in MPM. The 
evidence comes from case series such as that by Jackson et al.[51] They 
performed a retrospective review of 52 patients with MPM who underwent PCC. 
Their results showed that over 80% of patients were able to reduce their opioid 
requirements after the intervention and 38% stopped opioids completely. At nine 
weeks post PCC, 18 patients had a recurrence in their pain requiring an increase 
in analgesia. Mild weakness was noted in four patients and dysaesthesia was 
noted in two patients. The authors concluded that PCC had a low complication 
rate and was successful in treating pain associated with MPM. 
 
A Turkish group reported on 165 patients who underwent PCC, 19 of whom had 
MPM.[88] Of these 19 MPM patients, 13 were followed up for a median of 5.9 
months with six patients being lost to follow up. The only complication reported 
was one case of post cordotomy dysaesthesia and all patients had an 
improvement in pain after the procedure. The authors recommend that all 
patients with local pain due to MPM should be considered for PCC. 
 
2.8. Conclusions 
The pain associated with MPM is extremely challenging to manage. Patients will 
often require a variety of analgesic drugs, since opioids alone are often 
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insufficient to control the pain. It is not uncommon for patients to be on 
paracetamol, anti-inflammatories, opioids and adjuvant analgesics in addition to 
topical treatments. For some, this combination of drugs may provide adequate 
analgesia. However, many patients continue to suffer from pain despite this 
cocktail of drugs. In these patients, other options should be considered. 
Chemotherapy, while offering a potential survival advantage, does not appear to 
have a significant impact on pain. Radiotherapy may be of benefit to some 
patients, though prospective randomised data are lacking. Finally, again, despite 
a lack of prospective randomised data, neuroaxial pain therapy or cordotomy 
should be considered for patients whose pain is refractory to other treatments. 
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Chapter 3. Radiotherapy for the Treatment of Pain in 
Malignant Pleural Mesothelioma: A Systematic Review  
 
3.1. Introduction 
As discussed in chapter 2, radiotherapy can be given as a treatment option for 
pain control in patients with MPM. This chapter presents a systematic review 
which examines the evidence supporting the use of radiotherapy in treating pain 
in patients with MPM. 
 
3.2. Methods 
Ethical approval was not required for this systematic review. The following 
databases were searched electronically: Medline (1946-2013), Embase (1974-
2013) and CENTRAL (The Cochrane Library Issue 9, 2012). The keywords and 
search strategy are outlined in Appendix 1. The date of the last literature search 
was 5
th
 February 2013. 
 
3.2.1. Eligibility Criteria  
Studies which met the following criteria were eligible: 
MPM diagnosed histologically or radiologically 
Radiotherapy given with the intent of improving pain 
Documentation of the dose and fractionation of radiotherapy given  
Response rates to radiotherapy reported  
All types of study design potentially eligible  
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Studies published in English language 
Prospective assessment of pain response desirable but not essential.  
 
3.2.2. Appraisal Process 
Titles and abstracts of all the articles were reviewed independently by two 
authors (NM and BL). If the articles were thought to be potentially relevant, in 
accordance with the eligibility criteria, they were retrieved in whole. These were 
also reviewed independently by NM and BL. If both authors agreed that the 
articles met the eligibility criteria, they were included in this review. Where there 
was disagreement, the papers were discussed and a consensus reached. If there 
was doubt as to whether an article should be included or not, the primary authors 
were contacted to see if further information was available which might help to 
decide whether the study should be included or not. 
 
The potential for quantitative synthesis and meta-analysis was assessed. 
However, due to the small number of papers, limited reported information in 
many studies and varying primary endpoint measures, quantitative synthesis of 
results was not possible. Therefore, the salient findings of each paper are 
presented.  
 
3.3. Results  
The following number of articles was retrieved: 462 (Medline), 1007 (EMBASE) 
and 11 (Central). The literature search results are shown in Figure 11. Following 
the appraisal process described, eight articles were eligible  
 








































18 articles reviewed in 
full 
10 articles excluded 




 8 articles included 
See Table 2 
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Articles which met the eligibility criteria are shown in Table 2. Key aspects of 
each study are detailed. It is noted that no patients in any of the studies received 
pemetrexed based chemotherapy.  
 
Excluded articles are shown in Table 3. Most were excluded as either they did 
not examine whether radiotherapy improved pain control in MPM or they did not 
document response rates.  
 
In the majority of studies, pain response was assessed via retrospective case note 
review.[14, 32, 35, 89-91] Pain scores were only assessed prospectively in two 
studies. [33, 77] Patient numbers ranged from 19 to 189. All the studies are from 
single institutions with no multi centre studies performed. Dose and fractionation 
ranged from eight Gy in one or two fractions to 60 Gy in 30 fractions. The 
reported benefit ranged from no benefit seen to 69% response.[32, 77] 
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Table 2 - Summary of papers included in the review 

















36/12 Pain directed Descriptive only 54% Histology CT scanning 2 months after RT performed  
showing a 43% RR. No comment on association  












Not documented.  57% Histology Marked heterogeneity in dose and fractionation in this retrospective 















Descriptive only 50% for 4Gy per 
fraction, 39% for 
<4Gy per fraction 
Histology Change in fraction size not due to randomisation but rather reflective 
of a change in policy to treat sites of symptomatic disease only rather 




47 Single arm 
phase II 
40/20 Hemithorax Prospective pain 
score 0-4 
Mean pain score 
of 0.8 at baseline 
and 1.2 one month 
post RT 
Histology All patients referred to this institution entered into uncontrolled phase 
II study. Only 5 patients on opioids at study baseline and 27 had 














Descriptive only 60% Histology Authors acknowledged that follow up information detailing 
symptomatic response was inadequate. A wide variety of doses and 
fractionation schedules were prescribed. Confounding factors such as 
analgesic and steroid use and their influence on treatment were 








30/10 Hemithorax Prospective using 
three tools 
68% Histology for 17, 
radiology for 5 
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 *Number of patients in study **(hemithorax versus pain directed) *** method of recording Abbreviations: RT – radiotherapy RR – response rate 
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Table 3 - Excluded Papers 
Author and year Title Reason for exclusion 
Simone 2012 [92] Palliative care in the 
management of lung cancer: 
Analgesic utilization and 
barriers to optimal pain 
management 
Web based questionnaire on 
analgesic use in lung cancer 
and mesothelioma patients 
 Barbieri 2012[93] Effects of combined therapies 
on the survival of pleural 
mesothelioma patients treated 
in Brescia, 1982-2006 
Retrospective review. No 
mention of dose, fractionation 
or measures to assess 
analgesic benefit 
McAleer 2009 [94] Radiotherapy in malignant 
pleural mesothelioma 
Review article 
Stathopolous 2005 [95] Mesothelioma: Treatment and 
Survival of a Patient 
Population and Review of the 
Literature 
No mention of fractionation in 
this study 
Munter 2005 [96] Stereotactic intensity-
modulated radiation therapy 
(IMRT) and inverse treatment 
planning for advanced pleural 
mesothelioma 
Feasibility study looking at 
IMRT, not a study looking at 
pain relief from radiotherapy  
Zierhut 2004 [97] Radiation therapy of 
mesothelioma: the Heidelberg 
experience and future aspects 
No pain scores or assessments 
performed to assess response 
to radiotherapy in this 
retrospective review. No 
response rate documented 
Calavrezos 1988 [98] Malignant mesothelioma of 
the pleura 
No mention of radiotherapy in 
the paper 
Law 1984 [99] Malignant mesothelioma of 
the pleura: a study of 52 
treated and 64 untreated 
patients 
No mention of how pain or 
pain relief was measured. 
Radiotherapy not clearly 
given with intent of improving 
pain 
Wanebo 1976 [100] Pleural mesothelioma No comment on pain response 
or if any measures of pain 
were undertaken 
Shearin 1976 [101] Malignant pleural 
mesothelioma 
Retrospective review of all 
MPM patients rather than 
specifically patients with pain 








Based on the studies presented in this review, the evidence for radiotherapy in 
treating pain in mesothelioma ranges from Level 2- to 3.[102] Therefore, firm 
recommendations on the role of radiotherapy in the relief of pain in MPM cannot 
be made. Due to a combination of poor study design and small numbers of 
patients, none of the studies fully examines the role of radiotherapy in the 
treatment of pain in MPM. Indeed, in four of the eight studies, assessment of 
pain response was retrospective and in two of the other studies, it is not clear as 
to how the reported response rate was derived.[14, 32, 35, 89-91] These papers 
would have benefited from a prospective evaluation of pain response. The studies 
included in this review present little data on toxicity which would obviously be 
an essential requirement for future studies. 
 
In the studies included in this review, reported response rates vary from no 
benefit seen to 69%.[32, 77] Bissett’s study provides the strongest evidence for 
radiotherapy in this setting.[33] This prospective study used clear measures of 
pain response and reported a 68% response rate. However, hemi thoracic 
irradiation is rarely used nowadays due to concerns over toxicity. The only other 
study which assessed pain response prospectively was limited by the fact that 27 
of the 47 patients in the study had no pain at study entry.[77] Therefore, showing 
any improvement in this group would be difficult and it is not surprising that this 
study did not show a benefit in pain scores after irradiation. 
 
The most recent study in this review, by Jenkins et al, is to be commended since 
response was evaluated with a CT scan two months after treatment.[35] 
 
Chapter 3                                                                                                                                                   
57 
 
However, the study is limited by the lack of validated pain assessment tools. Two 
ongoing randomised phase III UK studies assessing the role of prophylactic drain 
site irradiation are prospectively assessing pain response.[30, 31] 
 
Although there is limited evidence to support radiotherapy for pain in MPM, it is 
recommended by the British Thoracic Society (BTS) as well as the European 
Respiratory Society and the European Society of Thoracic Surgeons (ERS/ESTS) 
[73, 103] However, the lack of strong evidence suggests that further work 
examining radiotherapy for pain in MPM is needed.  
 
Studying the role of radiotherapy in MPM is challenging. Firstly, it is a cancer 
that is associated with a poor survival.[14, 89] Even if patients do achieve a 
benefit in terms of pain response, this may be offset by a significant decline in 
performance status.[33] In these situations, patients might find it difficult to see a 
benefit from radiotherapy when their quality of life has deteriorated significantly. 
Secondly, there are several issues that are unique to MPM in terms of 
radiotherapy planning which make it a problematic area to study. Historically, 
attempts were made to encompass the entire volume of disease using hemi 
thoracic irradiation.[14, 33, 77] However, more recently, clinicians have tended 
to focus on treating sites of bulk disease, in an attempt to reduce toxicity and give 
larger doses to smaller areas.[35] In addition, treating the whole tumour to a dose 
sufficient to produce a response using traditional radiotherapy methods would be 
very toxic and not warranted in this patient population with limited life 
expectancy.[104] There have been no studies that have compared the two 
approaches. Instead, there has simply been a general trend towards treating 
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smaller field sizes in an attempt to reduce toxicity. Furthermore, radiotherapy 
prescribing in MPM is crude. For example, with bony metastatic disease, it is 
usually fairly easy to identify the painful lesion due to such features as bony 
destruction or erosion into a joint. Radiotherapy can then be targeted to that area 
with reasonable confidence that the correct area has been treated. However, with 
MPM, the pain is often widespread and may or may not correspond to disease 
bulk on CT imaging. The treating radiotherapist may have to compromise by 
directing treatment to areas of disease, which may or may not wholly correspond 
to pain. If radiotherapy is then not delivered to the appropriate area, the incorrect 
conclusion could be drawn that radiotherapy is not effective in pain palliation in 
this disease. However, if further imaging or other techniques were able to help 
the clinician target the radiotherapy more precisely to the area responsible for the 
pain, the potential palliative benefit of radiotherapy could increase significantly. 
 
Platinum/antifolate combination chemotherapy has become established as a 
treatment option for MPM which can be given with the aim of improving 
survival.[27, 28] Quality of life data from one of these studies have been 
published.[85] These data suggest that pain scores remained constant throughout 
chemotherapy. The authors concluded that stabilization of this and other 
parameters in a disease with as poor a prognosis as MPM was clinically 
significant. However, these data can similarly be interpreted as showing that 
chemotherapy provided no improvement in pain for these patients and so the 
benefit of chemotherapy in terms of symptom improvement is controversial. 
Furthermore, many patients diagnosed with MPM are not of adequate 
performance status to receive chemotherapy and very few actually receive this 
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treatment.[29] Therefore, chemotherapy does not appear to be an effective 
alternative treatment option to alleviate pain in MPM.  
 
3.4.1. Future work in this area 
There is clearly scope for further work in this area. Any future studies looking 
into the role of palliative radiotherapy in MPM should ideally involve optimising 
analgesia (both opioids and adjuvants) prior to radiotherapy delivery. This is 
imperative since a reduction in pain after radiotherapy is impossible to interpret 
if opioid requirements have increased significantly in that time. Furthermore, 
validated pain assessment tools should be used. An improvement in pain at six 
weeks is a meaningful primary endpoint for response to radiotherapy for bone 
metastases.[105, 106] The optimal time to assess response to radiotherapy in 
MPM is not known but four to six weeks would seem to be reasonable. 
Consideration should be given to studies with two dose levels to look for 
radiobiological effect. Furthermore, with modern day radiotherapy techniques 
such as RapidArc, it is possible to deliver higher equivalent doses to tumour 
while managing to limit dose to organs at risk, potentially allowing the 
possibility of randomised dose escalation studies. 
 
As outlined above, deciding what areas of disease to treat and what to omit is a 
real challenge for the clinical oncologist. At present, radiotherapy planning in 
MPM is driven by CT. PET-CT is now part of standard practice in the 
radiotherapy planning of non small cell lung cancer.[107] It also has a role in 
some aspects of MPM such as staging and assessing chemotherapy 
response.[108, 109] However the benefits of PET-CT over standard CT, in 
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defining clinical target volume in MPM are unknown and merit investigation.  A 
phase II study which addresses many of these issues is currently underway. 
(ISRCTN number: 10644347) This study aims to recruit 40 patients who will 
receive radiotherapy for pain control. The primary aim of the study is to establish 
the percentage of patients whose pain responds to 20 Gy in 5 daily fractions 
using 6 MV photons. 
 
In the age of personalised medicine, future research to identify biomarkers which 
are predictive of radiotherapy response would be of interest. While oestrogen 
receptor status is a well-established biomarker of response to hormonal therapy 
in breast cancer, very few such biomarkers exist with regards to radiotherapy 
response.[110] In nasopharyngeal cancer, it has been proposed that dysregulation 
of certain proteins may be involved in radioresistance.[111] It has also been 
proposed that, in bone metastases, certain features from quantitative sensory 
testing may be of value in predicting response to radiotherapy.[112] Such 
biomarkers would be helpful in MPM. If it can be predicted that there is a high 
probability that radiotherapy would be futile, then several visits to a cancer 
centre that may be a distance from the patient’s house could be avoided and 




In conclusion, the role of radiotherapy in the palliation of pain in patients with 
MPM remains uncertain. Future work in this area should evaluate pain response 
prospectively using validated pain assessment tools and ideally should be 
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performed with modern day radiotherapy techniques such as RapidArc aiming 
for randomised dose escalation studies. Studies which examine optimisation of 
radiotherapy planning and delivery and potential biomarkers of analgesic 
response are eagerly awaited.  
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Chapter 4. Methodology 
4.1. Overview 
It was clear that to meet the aims of this thesis, a clinical study would need to be 
developed. To this end, the SYmptom STudy of radiothErapy in MeSothelioma 
(SYSTEMS) was developed through peer review and subsequent funding. This 
chapter describes the development and methodology of the SYSTEMS study, 
which included a characterisation of MPM-related pain and a sub-study 
examining the role of PET-CT in radiotherapy planning in mesothelioma.  
 
4.1.1. Peer Review 
4.1.1.1. National Cancer Research Institute 
Once the initial study protocol was developed in 2011 (termed Radiotherapy for 
the Treatment of Mesothelioma Symptoms Study [RTMSS] initially), it was 
presented at the Clinical and Translational Radiotherapy Research Working 
Group (CTRad) of the National Cancer Research Institute (NCRI) on the 9
th
 
November 2011. Positive feedback was received which helped to guide the 
methodology and formal endorsement was secured.    
 
4.1.1.2. Beatson West of Scotland Cancer Centre  
The study was submitted to the In-House Trials Advisory Board (IHTAB) at the 
Beatson West of Scotland Cancer Centre (BWoSCC). IHTAB is an executive 
committee of the Cancer Research UK, Clinical Trials Unit, based in the 
Beatson. The group provides peer review for all studies which potentially are to 
be run through the trials unit and agrees on administrative responsibility, should 
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the study take place. The board was fully supportive of the study and agreed that, 
following successful procurement of funding, the study would be taken on as an 
investigator led trial within the Cancer Research UK, Clinical Trials Unit based 
in the BWoSCC.  
 
4.1.2. Funding 
The two year period of research was funded through grants from the June 
Hancock Mesothelioma Research Fund (JHMRF) and the Beatson Oncology 
Centre (BOC) Fund. The JHMRF awarded the Brother Peter Fellowship to 
support 50% of the costs of this research - Appendix 3. The BOC fund supported 
the remaining 50% of the costs - Appendix 3. This joint funding supported my 
salary and other research related costs such as clinical trial unit support. Funding 
for the PET-CT sub-study was supported by a grant from the British Lung 
Foundation (BLF) - Appendix 3.   
 
4.1.3. Ethics 
The study was approved by the West of Scotland Research Ethics Service - 
Appendix 6. The study was assigned International Standard Randomised 
Controlled Trial Number (ISRCTN) 10644347 and was badged by the NCRI.    
(http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID=14124).  
Procedures of the Declaration of Helsinki and Good Clinical Practice were 
followed. Written informed consent was provided by all patients - Appendix 4.  
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4.1.4. Research & Development (R&D) 
R&D approval was received from respective departments. The study, now called 
SYSTEMS, opened to recruitment on the 14
th
 June 2012.  
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4.2. Patients and Methods 
 
4.2.1. SYSTEMS study overview 
A multi-centre single arm phase II study of radiotherapy (20Gy in 5 daily 
fractions using 6 MV photons) for the treatment of pain in patients with MPM. 
The study design was informed by feedback received following grant and CTRad 
review. 
 
4.2.2. Considerations in Study Design 
There was much debate as to the optimal design for the SYSTEMS study. 
Consideration was given to a randomised controlled trial comparing radiotherapy 
with best supportive care since the evidence in support of radiotherapy in this 
situation is limited. However, palliative radiotherapy is recommended for pain 
control in both the British Thoracic Society (BTS) and European Respiratory 
Society/European Society of Thoracic Surgeons (ERS/ESTS guidelines.[73, 103] 
Therefore, it was not felt appropriate to design a study where one of the arms 
contradicted these guidelines. Furthermore, there was concern that patients might 
not consent to a study with a best supportive care arm when the standard 
treatment outwith the study setting was to receive the intervention.  
 
Once a study design incorporating a best supportive care arm was ruled out, 
thought was given to proceeding with a randomised study comparing different 
doses and fractionations in order to establish a gold standard regimen. In order to 
calculate the sample size required to demonstrate a difference in efficacy 
between two arms, the anticipated response rate to one of the arms would have to 
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be known. Again, given the limited data on the subject, no such accurate 
estimates could be made. If an inaccurate estimation were made, the expected 
study numbers could be imprecise. This would impact significantly on the 
likelihood of such a study providing the answer that was sought at the start of the 
study i.e. what the actual response rate to radiotherapy is in this setting. In view 
of this, it was decided that the primary objective of SYSTEMS was to establish 
the percentage of patients who had an improvement in pain following a standard 
dose of radiotherapy. It was anticipated that the results of the SYSTEMS study 
could then inform the basis of a subsequent randomised phase II study.  
 
There was much discussion as to whether to include only patients with a 
histological diagnosis or those patients with a diagnosis made following Multi 
Disciplinary Team (MDT) consensus. The decision was made to include the 
latter as this reflects clinical practice. The respiratory physicians in the West of 
Scotland were particularly influential in recommending including such patients 
given the difficulty that obtaining a histological diagnosis can present in this 
patient group. Furthermore, since MPM is an industrial cause of death, all cases 
require to be discussed with the procurator fiscal in Scotland and the coroner in 
England. Therefore, patients without a histological diagnosis should undergo a 
post mortem at which time a histological diagnosis can be made. It is noted that a 
histological diagnosis remains the cornerstone of cancer diagnosis and the 
decision to include non histologically diagnosed patients was not taken lightly. 
Attempts at histological diagnosis were encouraged whenever possible. 
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4.2.3. Study Design 
A multi-centre single arm phase II study of radiotherapy (20Gy in 5 fractions) for 
the treatment of pain in patients with MPM. A study schema is shown in Figure 
12. More frequent pain assessments were considered to help identify the optimal 
time to assess response. However, given that most patients were likely to be 
recruited from the West of Scotland and the prognosis was likely to be poor, 
more frequent hospital visits were felt to be too much of a burden for the patients 
and the visit schedule that was finalised on was felt to be sufficient. 
. 
  
Figure 12 - Study schema 
 
 
Chapter 4                                                                                                                                                   
68 
 
4.2.3.1. Pre Study Assessments 
One of the challenges of conducting a study examining a pain intervention in 
patients with advanced cancer is that changes in analgesia may occur during the 
study period. In such cases, it becomes very difficult to disentangle any 
improvements in pain as a result of the study intervention from any changes in 
concomitant analgesia. One of the ways this can be addressed is by stabilising 
pain and analgesia prior to study entry. This approach was adopted for potential 
patients in the SYSTEMS study. Prior to study consent, patients were reviewed 
by Drs. MacLeod and Laird (Palliative Medicine), often with multiple visits or 
telephone consultations over several weeks, enabling background analgesia to be 
optimised and pain stabilised, where possible, before study entry. This also 
resulted in some patients’ analgesia improving to the extent that their pain was 
no longer severe enough for study entry. Following optimisation of analgesics, if 
patients were eligible, written informed consent was obtained. Study assessments 
and timepoints are outlined in Table 4. 
 
4.2.4.  
At the baseline visit, an assessment of performance status was made along with a 
physical examination. All previous treatments for MPM – surgery, chemotherapy 
or radiotherapy - were documented along with the medication history which 
listed all medicines taken in the previous 24 hours. Baseline toxicity assessment 
was performed and all study questionnaires were completed. In order to improve 
compliance, rather than leaving the patient to complete the questionnaires, a 
study investigator completed the questionnaires based on the answers received 
from the patient. Quantitative sensory testing (QST) was performed. 
 




QST is essentially a detailed sensory examination of an area of the body and is 
described here. The painful area was mapped out. Dynamic mechanical allodynia 
was assessed using a standardised calibrated brush (Senselab 0.5mN Somedic, 
Sweden) stroked over a length of skin bilaterally. The contralateral chest wall 
acted as the control area. The patient was asked to describe how this sensation 
compared with the control area (hyperaesthesia, hypoesthesia or unchanged) and, 
if painful, was rated with a VAS of 0-10. 
 
Mechanical Detection Threshold (MDTH) and Mechanical Pain Threshold 
(MPH) were assessed with Von Frey monofilaments (Somedic, Sweden) using 
the Method of Levels technique to establish thresholds.[113] These constitute a 
series of 17 filaments of varying thickness, calibrated according to the force 
required to bend them. Mechanical pain sensitivity (hyperalgesia) was tested 
using noxious pin prick stimulus (Neurotips Owen Mumford). Response to warm 
(40 degrees Celsius) and cool sensation (25 degrees Celsius) was assessed using 
thermal rollers (Rolltemp, Somedic, Sweden). For all the stimuli, except for 
MDTH and MPH, actual thresholds were not measured. Responses were 
recorded as increased, reduced or equivalent sensation as the normal control 
side.[112]  
 
An American proteomics company, SomaLogic, has produced a 13-biomarker 
panel which may have a role in the diagnosis of MPM.[19] Before the study 
opened to recruitment, there was a verbal agreement with the company to take 
blood samples from patients at baseline and week 12. The aims of these blood 
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tests were twofold. The first aim was to validate the biomarker panel. The second 
aim was to explore the possibility that proteins could be identified which might 
help to predict a response to radiotherapy. On completion of the trial, SomaLogic 
were contacted regarding the shipping of the samples. At that time, we were 
informed that SomaLogic no longer had an interest in MPM and that the samples 
would not be analyzed. Therefore, no data on these samples can be presented in 
this thesis. However, the samples remain stored and future analyses may be 
performed on these samples. 
 
4.2.5. Week 1 Visit 
Patients were seen eight (+/-three) days after the start of radiotherapy for their 
week 1 visit. At this consultation, current medication was recorded, including 
analgesics in the past 24 hours. Any toxicity from radiotherapy was documented 
and the questionnaires were repeated. Current symptoms were documented. 
Following the week 1 visit, patients received weekly phone calls in order to 
monitor symptoms and assess analgesic requirements. 
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Table 4 - Study Assessments 
 Baseline Week 1 Week 5 Week 12 
Day 1 8 +/- 3 days 35 +/- 5 days 84 +/- 7 days 
Informed consent X    
Inclusion/exclusion X    
Vital signs X X X X 
Medical history X X X X 
Medication history X X X X 
Treatment history X X X X 
Physical examination X X X X 
ECOG Performance status X X X X 
CT SCAN 1 X   X 
Toxicity Assessment X X X X 
QST X  X X 
STUDY QUESTIONNAIRES: 
Brief Pain Inventory X X X X 
LANSS X X                      X X 
MPQ X X X X 
HADS X X X X 
EORTC QLQ C-30 & LC13 X X X X 
FSS X X X X 
NRS Dyspnoea X X                       X X 
NRS night sweats X X                       X X 
 
1
 within 8 weeks of first fraction of RT 
 




4.2.6. Week 5 visit 
Patients were seen 35 (+/-5) days from the start of radiotherapy. At this visit, all 
the study visits performed at week 1 were repeated. In addition, QST was 
repeated. A CT scan was requested to be performed prior to the week 12 visit. 
Week 5 and 12 visits were scheduled to take place in the hospital. However, if 
patients were unable to attend, efforts were made to see them at home. After the 
week 5 visit, the weekly phone calls continued until the week 12 visit.  
 
4.2.7. Week 12 visit 
At the week 12 visit, all assessments undertaken at week 5 were repeated. In 
addition, the CT scan result was discussed with the patient. Following this visit, 
patients were discharged back to their local oncology teams and study 
involvement ceased. During the course of the study, if patients’ analgesia 
required to be altered, this was done as per usual clinical practice. 
 
4.2.8. Study Centres 
The study was conducted in three regional oncology centres in the UK; the 
BWoSCC in Glasgow, Edinburgh Cancer Centre and Weston Park Hospital in 
Sheffield. The study initially opened in Glasgow since the West of Scotland has 
one of the highest incidences of MPM in the world. Edinburgh was then opened 
as a study site. Although there is not a high incidence of MPM in the east of 
Scotland, the Palliative Medicine Research Team (PMRT) in Glasgow is a 
component of the Edinburgh Palliative and Supportive Care Group (EPaS) at the 
University of Edinburgh, led by Professor Marie Fallon. Finally, Sheffield was 
 
Chapter 4                                                                                                                                                   
73 
 
added as a recruitment centre in May 2013, as there was a drive to boost 




In the SYSTEMS study, patients were recruited or excluded according to the 
following criteria: 
 
4.2.9.1. Inclusion Criteria  
1. ≥18 years of age 
2. Histological or MDT diagnosis* of mesothelioma 
3. Able to complete study assessments 
4. Life expectancy of at least 3 months based on clinical judgement 
5. Due to receive radiotherapy for pain resulting from mesothelioma (defined as 
index site) 
6. ECOG Performance Status 0‐2 
7. CT scan within 8 weeks of radiotherapy 
8. Worst pain >4/10 (0‐10 Numeric rating scale) corresponding to the index site. 
* MDT diagnosis consisted of a good history of asbestos exposure and CT 
imaging consistent with MPM 
 
4.2.9.2. Exclusion criteria 
1. Received chemotherapy or radiotherapy in the preceding six weeks that is 
likely to alter pain at the index site during the duration of the study 
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2. Planned chemotherapy during the period of the study that is likely to alter pain 
during the course of the study 
3. Psychotic disorders or cognitive impairment 
4. Co‐existing lung tumours at the time of study entry 




4.3.1. Rationale for Chosen Regimen 
The optimal dose and fractionation to be used in the treatment of pain in MPM is 
not established. Therefore, the choice of regimen in the SYSTEMS study was 
discussed at CTRad to help inform the choice. There are certain features of MPM 
that would suggest that a hypofractionated regimen would be preferable to a 
conventional fractionation schedule. The likelihood of improving outcomes by 
increasing dose per fraction varies among tumour types and is determined by the 
alpha/beta ratio of the tumour. Rapidly proliferating squamous cell carcinomas, 
such as head and neck and cervical cancer, have high alpha/beta ratios and 
benefit from treatment with small doses per fraction. Many non-squamous 
tumours with lower proliferation rates have low alpha/beta ratios and hence 
benefit from higher doses per fraction.[114, 115] While there are few data from 
which to estimate the alpha/beta ratio for MPM, its non-squamous histology, 
relatively low proliferation index, mesenchymal origin and apparent 
radioresistance are all consistent with a low alpha/beta ratio. Furthermore, in the 
palliative setting it is usual practice to deliver a short, hypofractionated 
schedule.[116] However, given that MPM is perceived to be a relatively 
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radioresistant tumour, consideration was given to a “hot” dose such as 36 Gy in 
six fractions treated over two weeks. Ultimately though, since this study was 
designed primarily to assess response rates to radiotherapy, it was felt that using 
a dose and fractionation that thoracic oncologists are familiar with was 
preferable. Twenty Gy in five fractions is a standard treatment regime used in the 
palliative setting in lung cancer and is recommended in the Royal College of 
Radiologists guidelines.[117] Favourable response rates with acceptable toxicity 
have been reported with this regimen.[118] Given the poor prognosis in MPM, it 





4.3.2. Radiotherapy planning 
4.3.2.1. Patient data acquisition 
A planning CT scan was performed on all patients on a General Electric light 
speed 16 slice scanner using the local thorax imaging protocol. Patients were 
scanned in the treatment position and asked to breathe normally. If tolerated, 
patients were treated with arms above their head. This position was selected as it 
is the conventional position for radical radiotherapy for lung cancer at the 
BWoSCC. Although when palliative treatment is being administered, patients are 
often treated with their arms down, the chosen position allowed more complex 
plans to be used if necessary. Continuous 2.5mm slices were acquired throughout 
the entire volume of both lungs from the cricoids process down to the iliac crest. 
Prior to the planning CT scan, patients were examined in a side room and radio-
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opaque wire markings were placed on the skin at the outer aspects of the painful 
areas, in order to help the clinician correlate the area of pain with the CT 
findings.   
 
4.3.2.2. Treatment Planning 
The first 12 patients in the SYSTEMS study and all patients in Edinburgh and 
Sheffield were planned using virtual CT sim placement using Advantage 
Windows version 4.3. Treatment was typically given in the form of a parallel 
pair though, occasionally, direct fields were used. Following Radiotherapy 
Management Group (RMG) approval, subsequent patients were volumed with an 
Eclipse plan produced by the physics team in the BWoSCC patients.  
 
The gross tumour volume (GTV) was defined as the volume of tumour that was 
felt to be responsible for the pain. Before having their planning CT scan, all 
patients were seen in a side room and wire markings placed on the skin to 
delineate the painful area. No attempt was made to include the entire volume of 
disease.[35] The GTV was outlined on each CT slice and grown by 1-2cm to 
form the planning target volume (PTV). Given that this was a palliative 
treatment, the GTV was not grown to produce a clinical target volume. Dose 
volume histograms (DVH’s) for organs at risk (OAR’s) were calculated in order 
to obtain full knowledge of the dose distribution. For all tumours, this involved 
outlining the oesophagus, heart, lungs and spinal cord. For right sided tumours, 
the liver was outlined whilst the stomach and spleen were outlined for left sided 
tumours. The ipsilateral brachial plexus or kidney was outlined if the PTV was 
within 5cm of it.  
 




4.3.2.3. Dose specification and treatment 
Patients were treated on a linear accelerator operating at 6 or 10MV. The 
prescribed dose was 20 Gy in 5 daily fractions of 4 Gy. With Eclipse planning, 
the aim was to have homogeneity between 95% and 107% of the ICRU reference 
point across the PTV, according to the International Commission on Radiation 
Units (ICRU) reports 50 and 62. However, as this was a palliative treatment, the 
ultimate decision on whether or not to accept the plan was at the discretion of the 
treating Clinical Oncologist. The rationale for having an Eclipse plan for these 
patients was primarily to enable dose to OARs to be evaluated and to correlate 
this dose with acute toxicity. In general, the Eclipse plans were aiming to be 
straightforward plans, such as a parallel pair, in order to reflect the way in which 
most patients are treated outwith a study setting. 
 
4.3.2.4. OAR Definition 
Lungs: Contoured on every slice from apex to base. 
Oesophagus: Outlined on every slice from the cricoids cartilage down to the 
gastro-oesophageal junction. 
Spinal Cord: The spinal cord was outlined 5cm above the superior border of the 
PTV and 5cm below the inferior border of the PTV. 
Heart: Contoured on all slices. The cranial border was taken as the infundibulum 
of the right ventricle and the apex of both atria. The great vessels were excluded 
as much as possible. The caudal border was defined as the lowest part of the left 
ventricle’s inferior wall that was distinguishable from the liver. 
Liver: The whole liver was outlined for right sided tumours. 
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Kidneys: If the PTV fell within 5cms of the kidney, the whole of the ipsilateral 
kidney was outlined and, if there was concern regarding dose to the contralateral 
kidney, it too was outlined. 
Stomach: The whole of the stomach was outlined for left sided tumours. 
Spleen: The whole of the spleen was outlined for left sided tumours. 
Brachial plexus: The brachial plexus was outlined if it was within 5cm of the 
upper border of the PTV. 
 
4.3.2.5. OAR Constraints for Radiotherapy Planning 
No data exist to guide OAR constraints for hypofractionated radiotherapy. 
However, given that this was a palliative treatment given with the aim of 
improving patients’ symptoms and wellbeing, there was caution with regard to 
dose constraints to OAR’s. Therefore, the following guidelines were established 
by the study investigators. 
Lung: No fixed upper limit of irradiated lung was set but keeping the volume 
receiving 20 Gy to <25% was strongly recommended. 
Oesophagus: The length of oesophagus in the treatment field was minimised 
where possible. However, 20 Gy in 5 fractions is a common palliative dose for 
oesophageal tumours and so no upper limit of oesophageal length within the PTV 
was set. 
Spinal Cord: As with oesophagus, the length of spinal cord within the treatment 
field was minimised where possible. Again, however, 20 Gy in 5 fractions is a 
common palliative dose to give to the spinal cord and so no upper limit on spinal 
cord length was set. 
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Heart: Dose constraints to the heart were difficult to quantify as there are at least 
4 targets; the myocardium, coronary arteries, conduction system and 
pericardium. Dose to the heart was minimised where possible with shielding 
considered, especially for left sided tumours. 
Liver: Dose to the liver was minimised where possible as the side effects of 
radiation hepatitis may negate any potential benefit from radiotherapy. There was 
scope within the protocol to permit more detailed radiotherapy planning in order 
to minimise the dose to the liver. 
Kidneys: Given that the kidneys are relatively radiosensitive, shielding to the 
ipsilateral kidney was recommended for low lying tumours. If this was not 
possible, the contralateral kidney was completely spared. 
Stomach: Dose to the stomach was minimised where possible to reduce acute 
toxicity, mainly nausea and vomiting. 
Spleen: For low lying left sided tumours, consideration was given to shielding 
the spleen in order to reduce the dose received. 
Brachial Plexus: For apical tumours, it was likely that at least part of the brachial 
plexus would lie within the PTV. It was felt that 20Gy in 5 fractions was within 
the tolerance of the brachial plexus and so PTV coverage was not compromised 
in order to reduce the dose to the brachial plexus. 
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4.3.3. CT assessment  
In order to be eligible for the study, all patients were required to have undergone 
a staging CT of chest and abdomen within 8 weeks of radiotherapy. For many 
radical studies, a CT scan is required to be performed within 4 weeks of 
radiotherapy. However, as this was a palliative radiotherapy study, it was felt 
appropriate to lengthen this to 8 weeks. The time between the CT and start of 
radiotherapy was minimised where possible. All patients underwent CT scanning 
at 12 weeks to assess response. A consultant radiologist who specializes in 
thoracic malignancies reviewed the baseline and week 12 CTs on a workstation 
using the Carestream PACS system. He was provided with a digitally 
reconstructed radiograph (DRR) outlining the treatment field for each patient. 
The radiologist was blinded as to the clinical response of each patient. Response 
was assessed using the modified Response Evaluation Criteria In Solid Tumours 
(RECIST).[119] Within the treatment field, tumour thickness perpendicular to 
the chest wall or mediastinum was measured in two positions at three separate 
levels on thoracic CT scans. The sum of the six measurements defined a pleural 
uni-dimensional measure. If it was not possible to identify three separate levels 
of tumour in the treatment field or two positions within the same CT slice, as 
many tumour measurements as possible within the treatment field were made. 
A complete response was defined as disappearance of all visible disease with no 
new disease appearing within the treatment field. A partial response was defined 
as a >30% reduction in the total sum of the lesions. Stable disease was defined as 
a <30% reduction and <20% increase in the size of the sum of the lesions. 
Progressive disease was defined as a >20% increase in the sum of the lesions as 
per RECIST 1.1 guidelines.[120] The association between radiological response, 
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as outlined above, and clinical response, assessed via a 30% drop in the BPI 
score at 5 weeks, was compared. 
                                               
4.4.  Assessments    
4.4.1. Brief Pain Inventory (BPI) 
All questionnaires utilized in this study are attached in Appendix 5. 
 
The BPI is a multi-dimensional pain assessment tool. It was designed to serve 
two purposes; to measure the intensity of pain and to assess the level of 
interference of pain on daily function. It was developed for use in cancer patients 
and has been extensively validated in both cancer and non cancer patients.[121-
123]  
 
All questions in the BPI relate to the previous 24 hours. The section on pain 
intensity asks the worst, least and average pain as well as the pain right now. 
Subjects are asked to score each answer from 0-10 where 0 is “no pain” and 10 is 
“pain as bad as you can imagine”. It also asks the participant to rate the 
percentage of pain relief they experience from whatever pain treatments or 
medications they are currently on, ranging from 0-100. 
 
The second section of the BPI focuses on the level of interference of pain on the 
subject’s lifestyle, namely their general activity, mood, walking ability, normal 
work, relations with other people, sleep and enjoyment of life. Again the scores 
are from 0-10 with 0 corresponding to “does not interfere” and 10 representing 
“completely interferes” with each question that has been asked. 
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Once the questionnaire has been completed, the total BPI score can be calculated 
and repeated to assess the impact of an intervention on the subject’s pain. For the 
study, the total score at baseline was calculated. A pain response was taken as a 
30% drop in BPI score from the baseline assessment.[123] 
 
4.4.2. Short Form McGill Pain Questionnaire (SF-MPQ) 
The MPG is a scale for assessing pain using verbal descriptors. It was designed 
to allow patients to express the intensity and quality of their pain.[124] A short 
form version was developed in 1987.[125] In 2009, this was further modified in 
order to develop a single measure for both neuropathic and non-neuropathic 
pain.[126] Amongst other purposes, it was planned that this questionnaire, SF-
MPQ2, could be used in treatment response studies.  
 
4.4.3. Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) 
The LANSS was developed in 2001 as a tool to identify patients who are likely 
to have neuropathic pain.[127] It has been extensively validated.[128, 129] The 
assessment consists of two sections; a pain questionnaire and sensory testing. In 
the pain questionnaire, subjects are asked five yes/no questions concerning their 
pain. With the sensory testing, the subject is examined for allodynia and for 
altered pin-prick threshold. Combining the scores for the questionnaire and the 
sensory testing gives a maximum score of 24. A score of >12 suggests that 
neuropathic mechanisms are likely to be contributing to the patient’s pain, 
whereas a score of <12 suggests that neuropathic mechanisms are unlikely to be 
contributing to the patient’s pain. 
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4.4.4. Hospital Anxiety and Depression Scale (HADS) 
The HADS is a self-assessment scale used to screen for anxiety and depression. 
The scale has been validated.[130, 131] There are 14 questions in total, seven 
looking at depression and seven at anxiety. Each question has four possible 
answers which are rated from 0-3 with the higher the score, the worse the 
symptom. The maximum score is 42. A score of > 15 is suggestive of a major 
depressive disorder.[132]  
 
4.4.5. Fatigue Severity Scale (FSS) 
The FSS is an instrument designed to determine the level of fatigue from which a 
subject is suffering. There are nine statements and the subject is asked to rate 
their level of agreement with the statement from 1 (completely disagree) to 7 
(completely agree) giving a maximum score of 63. The final score represents the 
mean value of the nine scores. It was developed in 1993 and has been validated 
in different illnesses.[133, 134] 
  
4.4.6. Numerical Rating Scale for Dyspnoea (NRS) 
Given that dyspnoea is one of the most common symptoms in MPM, it was felt 
that having an assessment of dyspnoea at each study visit was important. 
Therefore, a NRS was used ranging from 0-10 where 0 was “no dyspnoea” and 
10 was “dyspnoea as bad as the patient could imagine”.  
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4.4.7. Numerical Rating Scale for Night Sweats 
It has been noted in previous studies that night sweats are a common symptom in 
MPM.[16] Therefore, it was felt that monitoring the effect of radiotherapy on 
night sweats would be worthwhile. As there is no standard scale to assess night 
sweats, a NRS was constructed. Scores ranged from 0-10 with 0 corresponding to 
“no night sweats” and 10 being “night sweats as bad as the patient can imagine”.    
 
4.4.8. European Organisation for the Research and Treatment of Cancer 
Quality of Life Questionnaire (EORTC QLQ-C30) 
The EORTC QLQ-C30 is a validated questionnaire designed to assess the quality 
of life of cancer patients.[135] It incorporates nine multi-item scales: five 
functional scales (physical, role, cognitive, emotional and social); three symptom 
scales (fatigue, pain, and nausea and vomiting); and a global health and quality-
of-life scale.    
 
As can be seen in the paragraphs above, with the exception of the NRS for night 
sweats, all of the questionnaires used in the SYSTEMS study have been 
validated. The first step in the validation process involves a questionnaire being 
proposed as a potential way of measuring a symptom, e.g. pain. The validation 
comes when the questionnaire is tested on a different set of patients and similar 
results are obtained.[136]  
 
4.5. PET-CT Sub-study 
As part of the SYSTEMS study (ISRCTN 10644347), a subgroup of patients 
underwent PET-CT scanning.  The study was performed in the BWoSCC.  The 
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study was approved by the institutional review board and all subjects provided 
written informed consent. Eligibility criteria were as per the main SYSTEMS 
study. Consecutive patients were recruited from May 2012 until December 2013.  
 
All patients underwent CT-based radiotherapy planning prior to PET-CT 
imaging. All planning CTs were captured on LightSpeed Simulator LS RT 16 
GE Medical CT scanner (GE Medical systems, Crawley, UK) using a 120kV 
automatic mA modulation range of 15-240mAs with 50cm Dual Field of View. 
Radio-opaque wire markers were positioned on the patient on the outer aspects of 
the painful areas to help correlate clinical and radiological findings. The Gross 
Tumour Volume (GTV) was defined as the volume of tumour that was felt by the 
clinician to be responsible for the pain. The GTV to PTV margin was 1.5cm. All 
patients were treated with 20 Gy in five fractions using a Varian Linear 
Accelerator. 
 
Prior to undergoing PET-CT imaging, patients were fasted for at least six hours 
and then imaged one hour after injection of 400MBq Fluorine-18-
Fluorodeoxyglucose (
18
F-FDG).  Imaging was performed using an integrated 
PET-CT system (Discovery-690, General Electric (GE) System, Milwaukee, WI, 
USA). To replicate the radiotherapy treatment position, patients were positioned 
supine on a radiotherapy flat bed insert and immobilised using a CIVCO 
posirest-2. LAP lasers were then used to position the patient centrally in the 
scanner. Whole body CT images were acquired using a 120kV automatic mA 
modulation range of 15-240mAs. The encompassed field of view was from the 
skull base to the upper thigh, with reconstructions performed at 2.5mm 
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increments. This was followed by whole body PET acquisition, encompassing 
the same transverse field of view as the CT. PET attenuation correction was 
based on the CT data and images were corrected for scatter and iteratively 
reconstructed using Time of Flight and SharpIR on a 192x192 matrix.  All 
acquired images and SUV data were exported to a dedicated GE workstation 
(ADW 4.5) for viewing and reporting.  
 
PET-CT images were assessed together, three months after the final patient 
received radiotherapy, in order to reduce recall bias. PET-CT images were 
transferred to a radiotherapy treatment planning system (Eclipse 10.0.42) into 
DICOM RT format. PET-CT images were then fused with CT planning images, 
termed Enhanced PET-CT (E-PET-CT). The window and level for the PET 
images were set according to a previously described protocol using a 7g/ml 
threshold.[137] To enable evaluation of whether SUV correlated with pain, 
maximum SUV (g/ml based on body weight) were recorded for both irradiated 
tumour and for tumour outwith the radiation field.   
 
Contouring was performed by three clinicians independently. Each clinician 
outlined a GTV and PTV based initially on the standard radiotherapy planning 
CT scan. Once each clinician had contoured all patients, they were then 
permitted access to the E-PET-CT. At this time, each clinician re-contoured a 
GTV and PTV using the E-PET-CT images again for all patients.  
 
The PET-CT scan did not influence the thoracic radiotherapy which the patients 
received. In order to ensure this was the case, patients had their radiotherapy 
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planned before they had undergone their PET-CT. It was also ensured that the 
patients had not started radiotherapy before having their PET-CT.  
 
4.6. Study endpoints 
4.6.1. Primary 
As the primary aim of the SYSTEMS study was to examine if radiotherapy is an 
effective treatment for MPM, the primary endpoint was to assess if there was a 
clinically significant improvement in pain 5 weeks following radiotherapy.  A 
clinically significant improvement in pain was defined as a > 30% reduction 
from baseline in total BPI score.[123] 
 
4.6.2. Secondary 
There were a large number of secondary endpoints, all of which were exploratory 
in nature. The rationale for this was to inform future randomised studies 
examining radiotherapy in MPM. Endpoints were assessed at weeks 1, 5 and 12 
weeks post radiotherapy with the primary analysis at week 5, unless otherwise 
stated. 
 Secondary endpoints were as follows: 
To examine the effect of radiotherapy on pain at weeks 1 and 12 post 
radiotherapy, assessed using the BPI. A clinically significant improvement in 
pain was defined as a > 30% reduction from baseline in total BPI score [121] 
To examine the effect of radiotherapy on dyspnoea using a numerical rating scale 
(NRS) for dyspnoea [138]  
To examine the effect of radiotherapy on mood using the HADS [139] 
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To examine the effect of radiotherapy on quality of life using the EORTC QLQ-
C30 questionnaire (version 3.0) including lung cancer module EORTC QLQ-
LC13 [135] 
To examine the effect of radiotherapy on fatigue using the Fatigue Severity Scale 
(FSS) [134]  
To examine the effect of radiotherapy on night sweats. This was assessed using 
an NRS for night sweats 
To characterise pain in MPM using the LANSS and the MPQ[125, 127] 
Quantitative Sensory Testing (QST) was performed in the West of Scotland 
patients to examine the somatosensory components of the index site and to 
identify any clinical biomarkers which may predict those more likely to respond 
to radiotherapy. This was performed at weeks 5 and 12 post radiotherapy and 
compared with baseline 
To assess radiotherapy toxicity at weeks 1, 5 and 12 as per the Common Toxicity 
Criteria for Adverse Events (CTCAE) 4.0 
To examine the effect of radiotherapy on tumour bulk. This was assessed by 
comparing CT scans at baseline with scans performed 12 weeks after 
radiotherapy 
To evaluate the relationship between the systemic inflammation and symptoms 
(pain, mood, dyspnoea, fatigue). Inflammation was assessed using CRP 
To examine if incorporating PET-CT data alters the Gross Tumour Volume 
(GTV) by more than 20%? (this cut off level was based on previous work and 
felt to be clinically significant)[140] 
To examine whether SUV uptake on PET-CT imaging is suggestive of increased 
likelihood of response to radiotherapy 
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To examine whether PET-CT alters staging.  
 
4.7. Statistical Considerations 
4.7.1. Sample size calculation 
The sample size was determined by the availability of patients and the fixed 
duration of the study. On average, in one year, 36 patients were treated with 
radiotherapy for pain in Glasgow and Edinburgh. Therefore, an estimate of 36 
patients per year was felt to be feasible. 
 
The study aimed to recruit 40 patients over an 18 month period.  Previous 
experience in cancer pain trials suggests that patients are keen to participate in 
clinical trials, with fewer than 10% of eligible patients declining to 
participate.[141] It was anticipated that this would be the case, especially as this 
was a non-interventional study. Based on historical data, approximately 54 
patients should potentially have been eligible in this period, indicating that the 
proposed sample size seemed achievable. An analysis of the MPM patients 
treated with radiotherapy in 2010 in Glasgow shows that 73% lived greater than 
3 months following radiotherapy. Therefore the majority of study patients should 
have been able to complete all assessments. 
 
To answer the primary endpoint, a sample size of 40 patients was calculated and 
this allowed the proportion of responders to be estimated within +/-15.5%, 
depending on the true underlying proportion. Table 5  shows the precision and 
corresponding 95% confidence interval (CI) limits that would be achieved for a 
range of proportions. 
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Table 5 - Proportion of responders 






20% 12.4% 7.6% 32.4% 
30% 14.2% 15.8% 44.2% 
40% 15.2% 24.8% 55.2% 
50% 15.5% 34.5% 65.5% 
60% 15.2% 44.8% 75.2% 
70% 14.2% 55.8% 84.2% 




The primary analysis determined the proportion of patients for whom 
radiotherapy is an effective means of treating pain in MPM at 5 weeks post 
radiotherapy, where a clinically significant improvement in pain is defined as a > 
30% reduction from baseline in total BPI score. The proportion of responders is 
presented along with the corresponding 95% CI. 
 
4.7.2.1. PET-CT analysis 
The difference in overall treatment volumes (%) between CT and E-PET-CT was 
assessed. The concordance in volumes (GTV) outlined between CT and E-PET-
CT was calculated using the Conformity Index (CI). A CI of 1 represented 
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complete concordance between the CT and E-PET-CT while a value of 0 
represented no concordance.[142]  
 
CT was defined as the reference parameter and E-PET-CT was the evaluation 
parameter. The difference in shape of treatment areas between CT and E-PET-
CT was assessed using Mean Distance to Conformity (MDC). The Centre of 
Gravity Distance (CGD) assessed the difference from the central point of the 
reference volume and the evaluation volume. The under contoured volume 
(UCV) was the volume that was contoured in the reference volume but not 
contoured in the evaluation volume and is expressed as a percentage. The over 
contoured volume (OCV) is the volume that is contoured in the evaluation 
volume that is not contoured in the reference volume and is expressed as a 
percentage. These parameters were calculated using ImsimQA version 3.0.77.  
 
Patients whose pain improved following radiotherapy were defined as pain 
responders. A pain response was defined as a 30% drop in the BPI score 5 weeks 
after radiotherapy. 
 
To facilitate analysis, parameters were averaged across the three clinicians for 
each patient. The comparison between E-PET-CT and CT was made using a 
Wilcoxon signed rank test. All analyses were performed in SPSS v22.0 (Chicago 
IL.). An exploratory analysis of maximum standard update value (SUV) was 
performed to see if there were any potential association between these values and 
pain response or overall survival. 
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4.7.2.2. Analysis for Pain Characterisation Study 
A clinician completed the questionnaires with all patients and the same clinician 
undertook QST in order to reduce inter-observer variability.  
 
Patient demographics and pain characteristics (MPQ, BPI) were summarised 
using proportions, and means and standard deviations (SDs) or medians and 
inter-quartile ranges (IQRs) as appropriate. BPI “average pain” and “worst pain” 
scores were related to the BPI interference scale using Spearman’s correlation. A 
further analysis of the BPI interference scale was undertaken to compare those 
patients with, and those without, neuropathic pain, using Mann–Whitney tests.   
 
4.7.3. Statistical Reporting 
Throughout, means and SD, or medians and interquartile ranges (IQR) are  used. 
CI are reported as 95%.  
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Chapter 5. Results – Is radiotherapy useful for treating 
pain in MPM?  
5.1. Participant Disposition 
The participant disposition is shown in the CONSORT diagram in Figure 13. 
From June 2012 until December 2013, 40 patients consented to the trial. Of 
these, 37 patients started radiotherapy, with 35 completing their prescribed 
course. All sites of pain were in the chest.  
 
5.2. Demographics 
Patient demographics are shown in  
Table 6. Thirty-five patients were male and the median age (IQR) was 71.50 
(65.00-76.00) years. The most common histological type of mesothelioma was 
epithelioid which was present in 21 patients (56.8%) and the majority of patients 
were PS 1 or 2. The median survival from the time of trial registration was 93 
days (CI 68-118). However, this differed depending on histological subtypes - 
epithelioid 124 days (83-165) versus sarcomatoid 65 (37-93), p=0.04. The mean 
(SD) time from initial diagnosis to study entry was 249.41 days (274.16). The 
median (IQR) baseline BPI score was 57 (42.0-65.5) and the median (IQR) 
baseline opioid dose was 55mg (25-210).  
 
 





























Figure 13 - Participant Disposition 





Completed week 1 assessment 
n= 32 




Pain <4/10 n=4 
Preferred RT outwith study n=1 
Poor performance status n=1 
Decline in performance 
status prior to RT n=1 
Incomplete baseline data 
n=2 
Decline in performance status during 
radiotherapy n=1 
Lying on treatment couch exacerbated 
pain n=1 
Incomplete data n=3 
Died  n=2 
Completed week 12 
assessment n = 18 
Died n=12 
 
Chapter 5                                                                                                                                                   
95 
 
Table 6 - Patient Demographics 
Characteristic  n % Median IQR 
Male Sex  35 87.5   
ECOG 
 0 3 7.5   
 1 18 45.0   
 2 19 47.5   
Time from diagnosis 
to study entry (days) 
   127 57-356 
Mesothelioma 
Histology 
Epithelioid 21 56.8   
Sarcomatoid 10 27   
Mixed 3 8.1   
Other 3 8.1   
Not available 3    
Metastases Present 11 28.9   
Absent 28 71.1   
Unknown 1    
Previous anti-cancer 
therapy  
Chemotherapy 14 36.8   
Radiotherapy 1*** 2.5   
*SD – Standard Deviation  **IQR – Interquartile Range *** Patient received port site 
radiotherapy 
 
5.3. Primary Endpoint 
At the time of primary endpoint assessment (week 5), 30 patients were evaluable. 
Three patients did not start radiotherapy, two patients failed to complete 
radiotherapy, two patients had died before week 5 and three further patients had 
deteriorated to the point that they were no longer able to complete the assessment 
- Figure 13. 
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The primary endpoint, based on an intention to treat analysis, was met by 14 
patients (35%) who had a clinically significant improvement in pain 5 weeks post 
radiotherapy. Nine patients (22.5%) had an improvement of > 60% in BPI score 
with five patients (12.5%) having a complete response (100% improvement in 
BPI).  Therefore, based on a complete case analysis of 30 evaluable patients at 
week 5, 47% (CI 28.3-65.7) of patients responded to the radiotherapy. Of the 14 
patients who responded to radiotherapy, eight had epithelioid histology, four had 
sarcomatoid and two had mixed histology. As a percentage of the total number of 
each of these histological subtypes, 38% of epithelioid patients responded, 40% 
of sarcomatoid and 66.6% of mixed histology. There was no statistically 
significant difference between histological subtypes in terms of response, p>0.05. 
 
5.4. Secondary Endpoints 
5.4.1. Pain Response 
At weeks 1 and 12, the pain response rate was 27.5% (CI: 14-6%-43.9%) and 
15.0% (CI: 5.7%-29.8%) respectively, on an intention to treat analysis. Based on 
a complete case analysis, the proportion of pain responders at week 1 was 36.7% 
(CI: 19.9%-56.1%) and at week 12 was 33.3% (CI: 13.3%-59.0). Although 32 
patients completed the week 1 assessment, two of them had incomplete data and 
so were not evaluable. Eighteen patients were evaluable at week 12.  
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Only four responders had an increase in their opioid dose between study baseline 
and endpoint, and in only one patient was this >20mg (MEDD). There was no 
difference in mean opioid dose between baseline and endpoint in the responders, 
p=0.627. There was no difference in the percentage change from baseline MEDD 
at week 1 (p = 0.577) or week 5 (p = 0.355) between responders and non-
responders. Of the 14 responders, nine were on simple and eight on adjuvant 
analgesics at baseline. A similar proportion (16/24) of the non-responders were 
on simple analgesics at baseline. Although a slightly higher proportion (17/24) of 
non-responders were on adjuvant analgesics at baseline compared with 
responders, this was not statistically significant, p=0.391. Throughout the 
duration of the study, only one patient was started on an adjuvant analgesic. 
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   Patient number of those evaluable at week 5 (1-30) 
Figure 14 – Changes in Pain/Opioid Dose following radiotherapy. 
(a) Waterfall plot of percentage change from baseline to week 5 in total BPI 
score, and (b) corresponding raw change from baseline to week 5 in MEDD. The 
dotted line indicates a 30% reduction from baseline BPI score, the “response” 
criterion.  
 
5.4.2. Quality of Life 
There was no change in global QoL for patients throughout the study when taken 
as a whole group. However, there was a trend suggesting an improvement in 
QoL in responders and a decline in global QoL in non-responders, although this 
was not statistically significant. The median improvement in QoL in responders 
was 12.50 (IQR -16.67 – 41.67) compared with a median decline of 12.50 (IQR -
25.00 – 0.00) in non-responders. In terms of specific quality of life components, 
there was a worsening of fatigue, appetite loss and nausea/vomiting scores. 
Fatigue scores at week 12 (p = 0.040) and nausea/vomiting at week 1 (p = 0.017) 
had significantly increased. There 
were, however, improvements in pain, dyspnoea, insomnia and constipation. Pain 
scores at week 1 (p = 0.005) and 5 (p = 0.034) and dyspnoea at week 1 (p = 
0.037) were significantly lower. There was no significant difference between 
responders and non-responders in the change in dyspnoea score at week 5 
(responders: median change 0, IQR -33 to 33; non-responders: -16.67, IQR -33 
to 0; p = 0.203). The greater improvement in non-responders may be due to the 
baseline dyspnoea score being higher than for responders, although not 
significantly so (p = 0.148). Only one patient had a cough which was recorded as 
grade 2 at all times including baseline.  
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5.4.3. Other Symptoms 
The effect of radiotherapy on other key symptoms is shown in Table 7. There 
was no significant change in any other secondary endpoints with the exception of 
night sweats which improved by week 5 (p=0.01). 
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 Table 7 - Symptom assessments between trial baseline and other timepoints 
 
5.4.4. Toxicity 
In Table 8, the percentage of patients with the most common symptoms and 
probable side effects from radiotherapy are reported. Differentiating side effects 
of radiotherapy from symptoms due to disease progression is extremely difficult. 
Therefore, symptoms were graded at baseline and at each visit. For instance, the 
incidence of grade 2 dyspnoea was 45.9% at baseline and 45.5% at week 5. As 















p Mean (SD) p 
Dyspnoea  
(0-10) 
4.46 (2.47) 4.19 (2.84) 0.44 5.26 
(2.35) 
0.09 4.95 (3.08) 0.26 
Sweats 
(0-10) 
3.44 (3.58) 3.16 (3.29) 0.22 2.00 
(3.02) 




5.86 (4.17) 4.90 (4.15) 0.23 5.66 
(4.58) 





6.86 (3.41) 6.97 (4.09) 0.83 7.41 
(4.15) 
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follow up compared with baseline. As such, it is concluded that the treatment 
was well tolerated with minimal toxicity. Only one patient had a delay in 
delivery of their radiotherapy due to radiotherapy induced odynophagia, however 
this patient had an apical tumour and their larynx was within the radiotherapy 
field. The patient had been given additional analgesia as prophylactic cover but 
had not taken it. On commencing the analgesia, the patient’s odynophagia 
improved considerably and he completed the radiotherapy. 
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Table 8 - CTCAE Grades for selected AEs at each trial timepoint 
 
Baseline Week 1 Week 5 Week 12 
n % n % n % n % 
Anorexia Grade 0/1 31 83.8% 31 83.8% 30 90.9% 17 85.0% 
Grade 2 4 10.8% 4 10.8% 3 9.1% 3 15.0% 
Grade 3 2 5.4% 2 5.4% 0 .0% 0 .0% 
Not assessed/ deceased 0 .0% 0 .0% 4 .0% 17 .0% 
Total 37 100.0% 37 100.0% 37 100.0% 37 100.0% 
Dyspnea Grade 0/1 17 45.9% 18 48.6% 14 42.4% 10 50.0% 
Grade 2 17 45.9% 17 45.9% 15 45.5% 6 30.0% 
Grade 3 3 8.1% 2 5.4% 4 12.1% 4 20.0% 
Not assessed/ deceased 0 .0% 0 .0% 4 .0% 17 .0% 
Total 37 100.0% 37 100.0% 37 100.0% 37 100.0% 
Fatigue Grade 0/1 13 35.1% 15 40.5% 12 36.4% 9 45.0% 
Grade 2 14 37.8% 14 37.8% 10 30.3% 6 30.0% 
Grade 3 10 27.0% 8 21.6% 11 33.3% 5 25.0% 
Not assessed/ deceased 0 .0% 0 .0% 4 .0% 17 .0% 
Total 37 100.0% 37 100.0% 37 100.0% 37 100.0% 
Hyperhidrosis Grade 0/1 35 94.6% 37 100.0% 31 93.9% 20 100.0% 
Grade 2 2 5.4% 0 .0% 2 6.1% 0 .0% 
Not assessed/ deceased 0 .0% 0 .0% 4 .0% 17 .0% 
Total 37 100.0% 37 100.0% 37 100.0% 37 100.0% 
Pain Grade 0/1 22 59.5% 35 94.6% 32 97.0% 18 90.0% 
Grade 2 4 10.8% 2 5.4% 1 3.0% 1 5.0% 
Grade 3 11 29.7% 0 .0% 0 .0% 1 5.0% 
Not assessed/ deceased 0 .0% 0 .0% 4 .0% 17 .0% 
Total 37 100.0% 37 100.0% 37 100.0% 37 100.0% 
Pleuritic pain Grade 0/1 27 73.0% 22 59.5% 16 48.5% 9 45.0% 
Grade 2 7 18.9% 6 16.2% 10 30.3% 6 30.0% 
Grade 3 3 8.1% 9 24.3% 7 21.2% 5 25.0% 
Not assessed/ deceased 0 .0% 0 .0% 4 .0% 17 .0% 
Total 37 100.0% 37 100.0% 37 100.0% 37 100.0% 
 
 
Chapter 5                                                                                                                                                   
103 
5.4.5. CT response 
Changes in disease bulk, assessed using CT, are shown in Table 9. Only 18 
patients were alive and/or well enough to undergo the week 12 CT. Of these, 
there was only one partial response, as assessed by the modified RECIST criteria 
for assessment of response in MPM.[119] None of the five patients who had 
radiologically progressive disease had a drop in their BPI score.  
 
Table 9 - CT response at 12 weeks evaluated as per modified RECIST 1.1 
 n % 
Assessment of overall 













Not evaluable 21 52.5% 
Total 40 100.0% 
1
CR – Complete Response  
2
PR – Partial Response   
3
SD – Stable Disease  
4
PD – Progressive Disease 
 
5.4.6. Planning Volumes 
The median Planning Target Volume (PTV) was 1046.70cm
3 
(IQR 731.50-
1339.90). There was no difference between the median PTV for responders - 
1004.00cm
3
 (IQR 585.20-1312.00) - and non-responders - 1104.85cm
3
 (IQR 
795.00-1356.85) suggesting the size of the PTV does not correlate with the 
magnitude of response. A typical radiotherapy plan is shown in Figure 15. 
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Figure 15 – Radiotherapy Plan of a patient in the SYSTEMS study taken 
from the radiotherapy planning system at the Beatson WoSCC 
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The median survival of responders was 106 days (IQR: 86 to 126 days). Median 
survival was slightly lower in non-responders at 93 days (IQR: 18 to 168 days) 
but the difference was not statistically significant (p = 0.465). 
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Chapter 6. Results: F-18 FDG PET-CT influences target 
delineation when combined with standard CT-based 
radiotherapy planning in malignant pleural 
mesothelioma 
6.1. Demographics 
Sixteen patients were included in this part of the study and patient characteristics 
are shown in Table 10. All patients had a histological diagnosis of MPM. The 
majority of patients were male (n=14) and the median age (IQR) was 75 years 
(65-79). Median survival was 4.1 months (95% CI: 2.6 months to 5.5 months) 
from time of study registration. One patient was excluded from the study as he 
had a small, palpable tumour lump that was delineated by palpation rather than 
by imaging. Therefore, 15 patients were included in the analysis. In all patients, 
there was abnormal SUV uptake in the thorax. 
 
PET-CT resulted in upstaging of 9 of the 16 patients (56%), compared with 
conventional CT imaging. One patient was upstaged from T3 to T4 (6%), four 
patients had upstaging of nodal disease (25%) and five patients were found to 
have metastatic disease (31%), one of whom also had nodal upstaging. In two of 
these patients, this led to palliative radiotherapy being delivered, one of whom 
had impending spinal cord compression at the level of C5 which was above the 
scanning level of the staging CT, as seen in Figure 16. The bone metastases were 
not seen on the conventional CT of either patient. 
 




Table 10 - Patient Demographics (N=16) 
 n % 
Sex (M/F) 14/2 87.5/12.5 
PS (ECOG) 0/1/2 2/9/4 13/60/27 
Mesothelioma Histology 
  Sarcomatoid 3 18.8 
  Epithelioid 11 68.8 
  Mixed 2 12.5 
Previous Mesothelioma therapy  
 Chemotherapy 5 33 
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Figure 16 - PET-CT of a patient from the SYSTEMS study. Image taken 
from the National PACS archive. Area of spinal cord compression shown by 
arrow 
Image showing impending spinal cord compression not seen with conventional 
CT 
 
6.1.1. Volume size as delineated via CT and E-PET-CT 
Differences in PTV volumes delineated using CT and E-PET-CT are shown in 
   Patient number (1-15) 
 
Figure 17 In nine patients, PTV was larger when delineated using E-PET-CT 
compared with CT and in six patients it was smaller. Median E-PET-CT defined 
volume was increased by 4.14% compared with CT (IQR: -32.09% smaller to 
































   Patient number (1-15) 
 
Figure 17 – Changes in Radiotherapy Planning using PET-CT 
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Waterfall plot of median percentage difference in volumes (%) outlined by E-
PET-CT and CT. A positive difference indicates the volume outlined with E-
PET-CT is greater than with CT alone (n=15) 
 
6.1.2. Differences In Contouring Among Three Clinicians 
Analysis of CI, MDC, CGD, under/over-contouring and volume mismatch is 
shown in  
Table 11. The low value for CI (0.30) and high values for MDC (21.47mm) and 
CGD (16.40mm) as well as the high percentage of over- and under-contouring 
(44.00 and 46.67%, respectively), indicate significant discrepancies in the 
anatomical location of volumes outlined using CT or E-PET-CT.  
 
Table 11 - Summary data of key parameters comparing CT alone with E-
PET-CT (n=15) 
Parameter* (Unit/range) Median  IQR 
CI (0-1) 0.30 0.24 - 0.38 
MDC (mm) 21.47 16.73 - 33.70 
Volume Difference (%) 4.14 -32.09 - 22.25 
Total Volume Mismatch 
(%) 
92.33 77.33 – 130.33 
CGD (mm) 16.40 11.80 – 33.87 
UC Vol (%) 44.00 34.33 – 72.50 
OC Vol (%) 46.67 34.00 – 55.00 
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Figure 18 and Figure 19 show representative images illustrating differences in 
GTV contouring between individual clinicians when CT and E-PET-CT datasets 
were used to guide volume delineation. 
 




Figure 18 - CT planning in MPM. Image taken from the radiotherapy 
planning system at the Beatson WoSCC 
Image showing the differences in GTV outlining using CT alone by 3 clinicians. 
Green outline is clinician 1, pink is clinician 2 and cyan is clinician 3 
 
Figure 19 – E-PET-CT planning in MPM. Image taken from the 
radiotherapy planning system at the Beatson WoSCC 
 




Image showing the differences in voluming using E-PET-CT by 3 clinicians. 
Green outline is clinician 1, pink is clinician 2 and cyan is clinician 3 
6.1.3. PET-CT Analysis 
At the time of PET-CT acquisition, median blood glucose concentration was 5.0 
mmol/l
 
(range 4.2-6.3). Median SUV max was 17.6 (IQR 12.5-23.0). Median 
survival in patients with SUV max less than 17.6 was 3.7 months (95% CO 3.3-
4.1) compared with 4.1 months (95% CI 0-9.6) for patients with SUV max 
greater than 17.6, a difference that was not statistically significant. 
 
There was an association between SUV max and pain with SUV max being 
higher in the irradiated area than the non-irradiated area. The median difference 
in SUV max between these areas was 4.0 (IQR 0.8-8.6), p=0.035. 
 
Median SUV max for pain responders was 11.7 (IQR 11.7-22.1: n=5) compared 
with 16.7 (IQR 14.2-23.3: n=11) for non-responders. The variability and 
difference in group sizes makes it impossible to draw any robust conclusions 
about differences between responders and non-responders using SUV 
parameters. However, there would appear to be no obvious diference between the 
groups with regards to SUVmax (p=0.267).  
 
Chapter 7                                                                                                                                                 
113 
 
Chapter 7. Characterisation of Pain in MPM 
7.1. Demographics 
Forty patients consented to the study, 37 of whom completed the baseline 
assessments, see  
Table 6. The median age was 71.50 years (IQR 65.00-76.00) and median time 
from diagnosis to study entry was approximately four months (IQR 2-12). All 
patients were performance status 0-2. Epithelioid MPM was the most common 
histology, being present in 21 (56.8%) patients. Fourteen patients had completed 
platinum/pemetrexed based chemotherapy.  
 
7.1.1. Analgesic Use 
Analgesic use is shown in Table 12. Strong opioids were used by 32 patients 
(84.2%) whereas only three patients (7.9%) were on weak opioids. Twenty five 
patients (65.8%) were on adjuvant analgesics with the same number of patients 
on simple analgesics. 
 
Table 12 - Number of patients taking each type of analgesia at baseline 
Analgesia n % 





















Adjuvant analgesic and strong opioid 24 64.9 
*14 patients on pregabalin, 8 on gabapentin, 3 on amitriptyline 
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7.1.2. Pain characteristics 
The sensory component of the SF-MPQ is shown in Figure 20. The words most 
commonly chosen to describe the pain were “aching”, “tender” and “sharp” 





































































































Figure 20 – SF-MPQ 
Frequency of words used in the SF-MPQ (Sensory component) to describe the 










Figure 21 shows the individual components of the BPI.  The median (IQR) for 
average pain and worst pain was 4 (4-6) and 8 (6-8) respectively. General 
activity, normal work and enjoyment of life scored the highest on the 









































































































Figure 21 – BPI 
Boxplots of visual analogue components from baseline BPI questionaire 
 
Figure 22 shows scatterplots of the mean interference scores (MIS) from the BPI 
measured against worst pain score (WPS) and average pain score (APS) from the 
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BPI. The Spearman’s Correlation Coefficient for the MIS from the BPI and the 
WPS was 0.567, p<0.001. The Spearman’s Correlation Coefficient for MIS and 
APS was 0.556, p<0.0005. This shows a moderate positive association in worst 
and average pain scores with the mean interference score.  
 














































Figure 22 – Pain Score Scatterplots 
Scatterplots of (a) worst pain score and (b) average pain score against 
interference score from baseline BPI questionnaire 
 
7.1.3. LANSS 
Eleven patients, 31.4%, had a total LANSS >12 while 24 (68.6%) patients, had a 
LANSS < 12. An analysis was performed to assess whether there was any 
association between total LANSS, BPI and MPQ.  
 
The median total BPI for patients with a LANSS <12 was 52 (IQR 41.00 - 59.50) 
versus 69.50 (IQR 61.00 – 84.00) for patients with a LANSS >12, p=0.004. 
Similarly, comparing the LANSS with the SF-MPQ, the median SF-MPQ for 
those with a LANSS <12 was 10.00 (IQR 8.00 – 13.50) versus 15.00 (IQR 12.00 
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– 18.00) for patients with a LANSS >12, p=0.012. These data show that patients 
with a high LANSS also have a high BPI and a high SF-MPQ (see Figure 23), 




















































Figure 23 – Pain per LANSS category 
Boxplots of (a) total BPI and (b) MPG sensory scores at baseline split by LANSS 
category 
 
Response to radiotherapy was assessed looking at baseline LANSS and SF-MPQ. 
There was no evidence that the likelihood of response to radiotherapy is 
determined by the LANSS or SF-MPQ, p>0.05.  
 
A clinical diagnosis of neuropathic pain was made in 20 patients. Of the 11 
patients with a positive LANSS, eight also had a clinical diagnosis of 
neuropathic pain (73%). However, 11 of 24 patients with a LANSS <12 also had 
a clinical diagnosis of neuropathic pain (45.8%) suggesting that the LANSS may 
not be a particularly effective screening tool in this patient group, given the high 
false negative rate. Furthermore, a clinical diagnosis of neuropathic pain did not 
predict response to radiotherapy, with six patients with a clinical diagnosis of 
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7.1.4. QST results 
All QST parameters assessed in the hemithorax affected by MPM were 
compared to the contralateral side. These data are presented in Table 13. 
Sensation was assessed on the non affected side first using a brush and the result 
of the non affected side was regarded as normal. Sensation was then assessed on 
the affected side and the patient was asked whether they were more aware or less 
aware of the brush on this side or whether it was not different from the non 
affected side. If the patient was more or less aware of the brush on the affected 
side, this was regarded as abnormal sensation. Abnormal sensation to brush 
stimuli was seen in 13 patients (50%). Detection threshold was altered in 29 
patients (87.9%). In terms of pain threshold, this was abnormal in n=16 (78.8%) 
of patients. Sensation to cold stimuli was altered in 24 of patients (75%). With 
regards to the warm stimuli, this was altered in 19 patients (59.4%). Pin prick 
sensation was abnormal in 19 (63.4%). Finally, in terms of wind up, this was 
abnormal in 21 (70%).  
 






area Missing Total 
Brush 5 8 13 14 40 
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19.2% 30.8% 50.0% - 100.0% 
Detection 
Threshold 
12 17 4 7 40 
36.4% 51.5% 12.1% - 100.0% 
Pain 
Threshold 
11 15 7 7 40 
33.3% 45.5% 21.2% - 100.0% 
Cool 13 11 8 8 40 
40.6% 34.4% 25.0% - 100.0% 
Warm 13 6 13 8 40 
40.6% 18.8% 40.6% - 100.0% 
Pin Prick 8 11 11 10 40 






area Missing Total 
Wind Up 6 15 9 10 40 
20.0% 50.0% 30.0% - 100.0% 
 
Further analyses were performed to ascertain whether there was an association 
between specific QST characteristics, namely pin prick, hot and cold sensation, 
and the scores obtained in the BPI, LANSS or MPQ. The median MPQ score in 
those with abnormal QST cool sensation was 12 (IQR 9.5 – 16.5) compared with 
a median MPQ score of 6.5 (IQR 5.0 – 11.5) in those with normal cool sensation. 
This was a significant difference between those two groups of patients (p = 
0.016). There was no such relationship between MPQ and normal or abnormal 
hot sensation (p = 0.697). There was also no relationship between total BPI and 
any of the three selected QST assessments. With regards to the QST data and 
LANSS, all eight patients, in whom pin prick sensation was assessed, who had a 
LANSS > 12, had abnormal pin prick sensation whereas only nine of the 20 
patients (45%) with a LANSS < 12 had abnormal pin prick sensation (p = 0.010). 
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Analysis was also performed to investigate whether there were any particular 
QST characteristics which would suggest a higher likelihood of response to 
radiotherapy. Unfortunately, no such association was seen though the numbers 
were small. 
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Chapter 8. Discussion  
8.1. Is Radiotherapy an effective treatment for pain in MPM? 
The SYSTEMS study is the largest trial to date which examines the role of 
radiotherapy in MPM and the first to use validated assessment tools in this 
setting. The findings support the hypothesis that radiotherapy is an effective 
treatment for a proportion of patients with MPM related pain, with 35% of 
assessable patients experiencing a clinically meaningful improvement in their 
pain. Of these, 12.5% had a complete improvement in their pain. There were no 
specific features that differentiated the complete responders from the other 
patients though this may be due to the small number of complete responders. 
There was no association between pain response and improvement in any other 
symptoms, therefore, palliative radiotherapy in MPM should only be considered 
for pain control. 
 
8.1.1. Previous Work In This Area  
There is a lack of previous work in this area, with which to compare our findings, 
as shown in a recent systematic review.[34]  The only other prospective study 
which has examined radiotherapy in MPM reported on 22 patients who were 
treated with hemi-thoracic irradiation using Cobalt-60 machines at a dose of 30 
Gy in 10 fractions. Pain scores improved in 13 patients one month after 
radiotherapy with no increase in analgesic requirements. Validated pain 
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The findings of the present study are therefore of interest and provide evidence to 
support radiotherapy as a useful modality for treating pain in MPM. Of particular 
note is that in 12.5% of patients a complete analgesic response was recorded, 
providing grounds for optimism for future work in this area.  
 
8.1.2. Specific Study Characteristics 
There are certain characteristics of the study population which should be 
highlighted. Only 35% patients had received prior chemotherapy, which is lower 
than would be anticipated for patients with MPM. Also, the median age of 
patients in the study was 71 years compared to 60 years in previous studies 
examining the use of chemotherapy in MPM.[27, 28] Furthermore, an 
epidemiological study showed that, over a four year period, only 54 of 146 
patients were considered fit for chemotherapy and of them, only 28 (18%) 
received chemotherapy.[29] Therefore the figure reported in the present study 
appears to be representative of the population from which the study patients were 
recruited.  
 
The percentage of patients in the study with epithelioid histology was 56.8%. 
This is perhaps lower than would have been anticipated and is certainly lower 
than either of two phase III chemotherapy trials which showed a survival 
advantage for cisplatin in combination with an anti-folate agent.[27, 28] 
Sarcomatoid histology, seen in 27% of patients in this study compared with 
between 1% and 8% in the chemotherapy studies, is associated with a 
significantly worse prognosis than epithelioid histology.[27] This would suggest 
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that patients receiving radiotherapy for pain control are a very different 
population from those studied in previous chemotherapy trials.  
 
Despite the improvement in pain control, there was no improvement in QoL or 
other symptoms, although there was a trend towards improved QoL in those who 
responded to radiotherapy. There may be many explanations for this: primarily, 
these patients are near the end of life as shown by the median survival of 3.1 
months in this trial. Quality of life naturally deteriorates during this time and 
multiple symptoms co-exist in MPM such as dyspnoea and fatigue which are 
unlikely to be influenced by an improvement in pain. Similar results have been 
found in chemotherapy studies in MPM where no QoL improvements have been 
observed.[16] This may also reflect a generic problem associated with attempts 
to study QoL outcomes in patients with advanced cancers, in which patient 
attrition and general deterioration make it very difficult to detect treatment 
related changes in QoL.  
 
As can be seen from the short median survival of patients in the SYSTEMS 
study, this is a frail population with poor life expectancy. Given that there were a 
number of questionnaires needing completed at each visit, it was felt to be in the 
patients’ best interests for a study investigator to help the patient complete the 
questionnaires. Although this is not how these questionnaires were validated, it 
proved to be a most useful decision as many patients found the help provided by 
the study investigator to be most useful. Also, on several occasions, it became 
clear to the investigator that some patients were struggling to complete all the 
questionnaires. In these situations, the study investigator did not ask the patient 
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to complete all questionnaires and finished the consultation early. Had this 
approach not been adopted, the patient may have struggled on and put 
themselves under unnecessary stress in the process.   
 
8.1.3. Study Limitations 
The main limitation of the study was the small sample size. However, this was 
designed as a single arm observational trial and the main aim was to inform 
future, larger scale studies; this has been achieved. Another limitation was the 
very high attrition rate within the trial with only 75% of patients being evaluable 
five weeks after radiotherapy.  This highlights the poor survival of these patients 
and the fact that, by the time most patients with MPM develop significant, 
uncontrolled chest pain, they are usually at an advanced stage of their illness. A 
potential limitation was the choice of radiotherapy regimen. There is no 
consensus on the standard radiotherapy technique for treating patients with MPM 
with palliative intent, so a rather conservative dose and regimen were selected 
because of wide use in the study centres. We cannot comment on whether pain 
improvement persisted beyond the twelve weeks of the study. 
 
8.2. The role  of  PET-CT in radiotherapy planning in MPM 
8.2.1. Main Findings 
The findings from the PET-CT sub study show that incorporation of PET-CT 
imaging in the radiotherapy planning process alters the anatomical location of the 
target volume in patients with MPM. There was an association between SUV 
max and location of pain with the painful (irradiated) area having a higher SUV 
max than the non-painful (non-irradiated) area. This did not translate into 
 
Chapter 8                                                                                                                                                 
125 
 
increased response rates to radiotherapy in patients with higher SUV max values. 
PET-CT also upstaged a large percentage of patients. In two patients this led to 
palliative radiotherapy being delivered to sites of painful bony disease. One of 
these patients had imminent spinal cord compression in the cervical spine. 
 
8.2.2. Previous Work 
Comparing our findings to previous work is difficult as, to date, only one other 
study has examined PET-CT in radiotherapy planning in MPM.[40] Pehlivan and 
co-workers examined 13 patients and outlined GTV and PTV using both CT and 
fused PET-CT. All target volume delineation was performed by one radiation 
oncologist and checked by another. The GTV comprised of macroscopic primary 
tumour along with involved hilar and mediastinal lymph nodes.  The authors 
found that in 12 of the 13 patients, the GTV and PTV were significantly smaller 
using the fused PET-CT images – mean GTV reduction of 47.1% (+/- 28.4%). 
The main difference between the previous work and the present study is that we 
assessed palliative radiotherapy planning as opposed to radical radiotherapy 
which may well account for differences in the findings.  
 
8.2.3. Implications Of Study Results 
The present study increases the knowledge base in two ways. Firstly, the use of 
PET-CT significantly alters the location of the target volume. It is also of interest 
that the SUVmax was higher in the irradiated areas, which, by default, were the 
areas where pain was the most severe. This association had not previously been 
reported in lung cancer or MPM per se, however it had been demonstrated that 
increased SUV uptake is associated with increased pain and subsequent response 
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to radiotherapy in bone metastases.[143] The present study was not powered to 
examine whether increased SUVmax predicted increased the likelihood of 
response to radiotherapy, but this would be of interest in future work. Indeed 
PET-CT based treatment planning could be used to target all metabolically active 
disease, which, presumably, causes the most pain.   
With regards to factors which influence SUV uptake, it has been shown that 
infection in patients with prosthetic hips can be readily identified via FDG PET-
CT.[144] Furthermore, inflammation has been shown to be associated with 
increased SUV uptake.[145] No studies have looked at SUV uptake from FDG 
PET-CT in relation to the pathophysiology of pain. 
.   
 
8.2.4. Current Role of PET-CT in MPM 
PET-CT is being used with increasing frequency in MPM. It can play a role in 
differentiating benign from malignant lesions and help target the most suitable 
lesion for biopsy.[146] In addition, it has been shown to be effective in pre-
operative imaging, particularly with regards to detecting distant metastases.[147, 
148] Given the diffuse, infiltrative nature and asymmetric growth pattern of 
MPM, measuring response to treatment with CT is extremely difficult. One study 
looked at changes in total glycolytic volume (TGV) in PET-CT and suggested 
that a decrease in TGV after chemotherapy, related to a survival advantage.[109]  
 
PET-CT can also be helpful for radiotherapy planning when there is significant 
atelectasis. Although contouring with PET-CT is generally smaller than with CT 
alone, one study did show that contouring with PET-CT can produce larger 
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volumes than when contouring with CT, which may be due to resolution 
effects.[149]   
 
PET-CT may also be useful in estimating prognosis. For instance, the presence of 
metastatic disease on PET-CT has, not surprisingly, been shown to be associated 
with poorer survival.[150] Furthermore, one study showed that patients who had 
an SUV max greater than 10 had decreased survival.[151] These findings were 
not replicated in the present study though this may be due to the small sample 
size and number of survival events. It is important to emphasise that there are 
many factors which can influence the SUV value such as blood glucose and 
timing from injection of the FDG to acquisition of the images so making cross 
study comparisons is difficult.[152]  
 
8.2.5. Study Limitations 
The current study has limitations. As has already been mentioned, the sample 
size is small which is a perennial problem in rare cancers. However, this is the 
largest study to date looking at PET-CT in radiotherapy planning in MPM. On 
reviewing the size of the GTV outlined by each clinician, it became clear that 
there was widespread variation in contouring. This degree of subjectivity is 
difficult to avoid since it is not known whether covering all PET avid disease is 
necessary for radiotherapy to be effective in terms of reducing pain. It is not 
known whether treating central disease is necessary or whether radiotherapy 
should focus on more peripheral disease looking, for instance, for chest wall 
invasion or nerve root irritation.   
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8.3. Characterising pain in MPM 
8.3.1. Main Findings 
Pain is a significant problem in MPM and patients scored highly on all pain 
questionnaires.  Pain also significantly impacted on day to day function and high 
levels of worst and average pain were associated with functional interference.  
 
Pain in MPM has been reported as having a strong neuropathic component; 
related to its local effects on the neurovascular bundle.[153] It was of interest 
that in the present study, only 20 patients (54%) had a clinical diagnosis of 
neuropathic pain and in such patients it would be reasonable to use appropriate 
neuropathic agents. Pain response to radiotherapy did not appear to be affected 
by the presence of a neuropathic element to the pain, with a similar proportion of 
patients responding to radiotherapy in both groups. Of the 20 patients who had a 
clinical diagnosis of neuropathic pain, only eight had a positive LANSS. In 
addition, 11 of the 24 patients with a negative LANSS had a clinical diagnosis of 
neuropathic pain. Based on these data, it would appear that the LANSS is not a 
particularly effective screening tool for neuropathic pain in MPM.  
 
8.3.2. Previous Work 
This is the first study that characterises pain in MPM, therefore, we are unable to 
compare our findings with other previous work. However, similar work has been 
performed on cancer-induced bone pain (CIBP).[154] The work on CIBP showed 
that WPS was more closely correlated to MIS than APS. It is accepted that 
background pain in CIBP is easier to control than incident pain, but in MPM 
related pain, it would appear that both WPS and APS correlate with MIS, 
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suggesting that both background pain and incident pain are problematic in MPM 
patients. Therefore, the aim of analgesia should be to target both background and 
incident pain. 
 
8.3.3. MPQ Descriptors  
With regards to the SF-MPQ descriptors, the most commonly used words in this 
study were “aching”, “tender” and “sharp”. In previous work examining CIBP, 
the most commonly used descriptors were “dull”, “sore”, “hurting” and 
“heavy”.[154] This would suggest that the character of pain in MPM is different 
and that, in part, this may be due to its underlying complex mechanism; 
nociceptive and neuropathic in combination. 
 
8.3.4. QST 
QST has never been studied in MPM patients. However, it has been studied in 
patients undergoing palliative radiotherapy for CIBP.[112] In CIBP, the main 
finding was that those patients who had normalisation of abnormal warm 
sensation, had greater improvements in pain scores.[112] This suggests that 
patients who have alteration in certain sensory characteristics are more likely to 
respond to radiotherapy. The present study did not show that any QST 
parameters predicted response to radiotherapy, despite marked sensory 
abnormalities in the affected side, with the majority of patients having altered 
pinprick, warm and cool sensation, as well as altered detection threshold; 
however the study was not powered to assess this.  
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It has been demonstrated that pain in MPM improves following radiotherapy in 
approximately 50% of patients.[155] Whilst these findings are encouraging they 
do mean that many patients who are treated with radiotherapy do not get an 
improvement in their pain. If biomarkers were identified which predicted those 
patients who were more likely to respond to radiotherapy, this may allow 
treatment to be stratified accordingly. The present study does not identify any 
factors. However it was not powered for this. Future studies examining 
radiotherapy for the treatment of pain in MPM should include biomarker 
collection to allow any predictive factors to be identified.  
 
8.3.5. Study Limitations 
The small sample size is a clear limitation and thus limited inference can be 
made from the findings. The sample size was based on the likely availability of 
patients and the fixed length of the study. All of the present aims were 
exploratory and should be examined further in larger cohorts. Another limitation 
is that the LANSS is a screening tool for neuropathic pain and not diagnostic.  
 
8.4. Future Work 
The improvement in pain seen in patients in the SYSTEMS study provides 
grounds for optimism in this area. Future work should examine dose escalation, 
both in terms of total dose and dose per fraction, since the likelihood of 
improving outcomes by increasing dose per fraction varies among tumour types 
and is determined by the α/β ratio of the tumour. While rapidly proliferating 
squamous cell carcinomas, such as head & neck or cervical cancer, have high α/β 
ratios and benefit from treatment with small doses per fraction, many non-
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squamous tumours with lower proliferation rates have low α/β ratios and hence 
benefit from higher doses per fraction.[114, 115] While there are few data from 
which to estimate the α/β ratio for MPM, its non-squamous histology, relatively 
low proliferation index, mesenchymal origin and apparent radioresistance are all 
consistent with a low α/β value. This approach would also have the advantage of 
reducing hospital visits and delivering palliative treatment in a timely fashion, 
which are clearly important issues in patients with limited survival.  
 
There is increasing evidence that not all tumour types respond to multiple small 
radiotherapy doses and growing support for the use of hypofractionated regimes 
in the palliative and curative treatment of selected tumour types.[156-158] 
Therefore dose escalation studies, ideally delivered using advanced radiotherapy 
techniques (e.g. intensity modulated radiotherapy) to help provide adequate 
coverage of bulky areas of disease, while sparing critical normal tissues 
including lung and liver, would seem the obvious next step. Indeed, funding has 
been secured for a follow on study, SYSTEMS 2, comparing 20 Gy in 5 daily 
fractions with 36 Gy in 6 fractions on alternate days. The hypothesis in this study 
is that by increasing the dose of radiotherapy, a higher proportion of patients will 
experience improved pain control.  
  
The role of PET-CT in radiotherapy planning could be researched further by 
looking at its potential role in radical radiotherapy planning. Radical 
radiotherapy in MPM is challenging given the very large fields required to cover 
the entire pleura and the multiple OARs which need to be considered. Given that 
MPM is so avid on PET-CT, this investigation could prove helpful in target 
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delineation. With advancing radiotherapy techniques, such as RapidArc, then 
delivering a radical dose of radiotherapy to the pleura may be possible. 
 
In terms of palliative radiotherapy, it would appear that the next step would be a 
study looking at pain outcomes in patients who were randomised to have their 
radiotherapy planned with the addition of PET-CT, compared with those who 
had radiotherapy planned using standard CT. In the PET-CT sub study described 
in this thesis, the area of pain corresponded to the highest SUVmax on the PET-
CT. This may help with target delineation which could subsequently result in 
improved palliation and pain control.  
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Chapter 9. Conclusion 
My thesis set out to examine radiotherapy for the treatment of pain in MPM. Pain 
can be a major problem in this condition and is not managed particularly 
effectively with standard analgesics. Some patients continue to experience severe 
pain despite intensive palliative medicine input and are often referred for non 
pharmacological pain interventions. Radiotherapy is one such intervention for 
this pain but a strong evidence base for this is lacking. Most studies in this setting 
are retrospective and no consensus can be reached, based on the currently 
available data, as to the optimal dose and fractionation that should be delivered. 
Given the huge variety in reported response, prior to the SYSTEMS study, it was 
not possible to give an accurate estimate as to the likelihood of symptomatic 
benefit.  
 
With the high incidence of MPM in the West of Scotland, it seemed appropriate 
that a study looking at radiotherapy for pain control in this population should be 
based in this geographical area. However, conducting such a study in MPM 
patients is challenging for a variety of reasons, not least because of the poor 
functional status of the patients. Furthermore, radiotherapy for pain control is not 
standardised with confusion as to whether large treatment fields should be used 
with the risk of increased toxicity or treating smaller areas with the risk of not 
treating the area of disease that is causing the pain. In addition, by the time most 
patients with MPM develop severe pain, they are often approaching the final 
stages of their lives which again makes conducting a study in this group of 
patients difficult. Despite  these challenges, the SYSTEMS study recruited 
successfully and is the largest prospective study ever conducted in this 
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population. The study showed that palliative radiotherapy can be an effective 
method of treating pain in MPM, and, in a proportion of patients, can be 
associated with dramatic improvements in pain. The use of wire markings in the 
radiotherapy planning stage proved highly successful at helping to localise the 
area of tumour to be targeted, and helped to confirm that large fields are not 
necessarily required for patients to obtain symptomatic benefit. These findings 
provide a foundation for  current practice and highlight that radiotherapy studies 
in advanced cancers and complex tumours such as MPM are feasible.  
 
The PET-CT sub study also provided useful data. Disease was PET avid in all 
patients and PET-CT improves multiple parameters in radiotherapy planning, 
compared to CT alone, including the conformity index and the centre of gravity 
distance. PET-CT also resulted in upstaging in a significant percentage of 
patients and should be considered as a staging investigation prior to any radical 
treatment.  
 
Funding has been secured from the June Hancock Mesothelioma Research Fund 
(£249,932) for a dose escalation study. It was hoped that the work within this 
thesis would inform future work in MPM and this aspect is being realised. 
Improving the care of patients with mesothelioma remains a priority and it is 
hoped that the research presented within this thesis has moved the research 
agenda forward.  
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Appendix 1 – Literature Search 
Database: Ovid MEDLINE(R) <1946 to February Week 1 2013> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     (tumour$ and pleura).tw. (526) 
2     (tumour$ and peritoneum).tw. (317) 
3     (tumour$ and pericardium).tw. (157) 
4     mesothelioma.tw. (9750) 
5     (1 or 2 or 3) and 4 (201) 
6     (pleura$ and neoplasm$).tw. (1318) 
7     4 and 6 (370) 
8     exp Pleural Neoplasms/ (10417) 
9     4 and 8 (4509) 
10     exp Mesothelioma/ (10661) 
11     mesothelioma$.tw. (10535) 
12     5 or 7 or 9 or 10 or 11 (12725) 
13     exp Radiotherapy/ (127441) 
14     exp Radiation Oncology/ (2291) 
15     (thoracic$ and radiotherap$).tw. (2223) 
16     (thoracic$ and radiation$).tw. (2594) 
17     (radiation and therap$).tw. (68794) 
18     13 or 14 or 15 or 16 or 17 (170438) 
19     12 and 18 (491) 
20     exp mesothelioma/ (10661) 
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21     exp Pleural Neoplasms/ (10417) 
22     ((pleur$ or mesothelioma$) adj2 (malignan$ or tumor$ or tumour$ or oncolog$ 
or neoplas$ or cancer$ or carcinom$)).ti,ab. (9214) 
23     mesothelioma$.ti,ab. (10535) 
24     21 and 23 (4755) 
25     20 or 22 or 23 or 24 (15547) 
26     exp Radiation Oncology/ or exp Radiotherapy/ (128695) 
27     rt.fs. (149152) 
28     (radiotherap$ or irradiat$ or radiation$).ti,ab. (392148) 
29     26 or 27 or 28 (464267) 
30     exp palliative care/ or exp terminal care/ or exp hospice care/ or exp hospices/ 
(72184) 
31     (palliative adj2 care).ti,ab. (11827) 
32     (end adj2 life).ti,ab. (9501) 
33     (palliat$ or EOLC or dying).ti,ab. (62722) 
34     (terminal$ adj2 (ill$ or patient$ or care)).ti,ab. (8723) 
35     30 or 31 or 32 or 33 or 34 (112246) 
36     25 and 29 and 35 (163) 
37     19 or 36 (572) 




Database: Embase <1974 to 2013 February 05> 
 




1     (tumour* and pleura).tw. (743) 
2     (tumour* and peritoneum).tw. (469) 
3     (tumour* and pericardium).tw. (228) 
4     mesothelioma.tw. (12671) 
5     (1 or 2 or 3) and 4 (291) 
6     (pleura* and neoplasm*).tw. (1732) 
7     4 and 6 (486) 
8     exp pleura tumor/ (9767) 
9     4 and 8 (4949) 
10     exp mesothelioma/ or exp malignant mesothelioma/ or exp pleura 
mesothelioma/ (15572) 
11     mesothelioma*.tw. (13676) 
12     5 or 7 or 9 or 10 or 11 (17636) 
13     exp radiotherapy/ (345183) 
14     (thoracic* and radiotherap*).tw. (3381) 
15     (thoracic* and radiation*).tw. (3993) 
16     (radiation and therap*).tw. (96734) 
17     13 or 14 or 15 or 16 (382277) 
18     12 and 17 (1208) 
19     exp mesothelioma/ or exp malignant mesothelioma/ or exp pleura 
mesothelioma/ (15572) 
20     exp pleura tumor/ (9767) 
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21     ((pleur* or mesothelioma*) adj2 (malignan* or tumor* or tumour* or oncolog* 
or neoplas* or cancer* or carcinom*)).ti,ab. (12294) 
22     mesothelioma*.ti,ab. (13676) 
23     20 and 22 (5209) 
24     19 or 21 or 22 or 23 (21484) 
25     exp cancer radiotherapy/ or exp radiotherapy/ (345183) 
26     (radiotherap* or irradiat* or radiation*).ti,ab. (526381) 
27     rt.fs. (231732) 
28     25 or 26 or 27 (698149) 
29     exp palliative therapy/ or exp terminal care/ or exp hospice care/ or exp 
hospice/ (92654) 
30     (palliative adj2 care).ti,ab. (17191) 
31     (end adj2 life).ti,ab. (12740) 
32     (palliat$ or EOLC or dying).ti,ab. (85063) 
33     (terminal$ adj2 (ill$ or patient$ or care)).ti,ab. (10812) 
34     29 or 30 or 31 or 32 or 33 (145579) 
35     24 and 28 and 34 (323) 
36     18 or 35 (1332) 




#1           MeSH descriptor: [Mesothelioma] explode all trees        82 
#2           mesothelioma:ti,ab,kw  (Word variations have been searched) 140 
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#3           #1 or #2                140 
#4           MeSH descriptor: [Radiotherapy] explode all trees          4505 
#5           radiotherapy:ti,ab,kw  (Word variations have been searched)    9707 
#6           #4 or #5                10488 
#7           #3 and #6            16    (13 of which were in CENTRAL database) 
 
CENTRAL -- 11  , of which we chose 0 
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25 February 2016 
 
 
Dr Barry Laird 
Institute of Genetics and Molecular Medicine 
University of Edinburgh 
Edinburgh Cancer Research Centre 
Western General Hospital, Crewe Road South 
Edinburgh EH4 2XR 
 
 
Dear Dr Laird 
I am pleased to confirm the award of a British Lung Foundation research grant as 
detailed below. 
The grant is subject to our Grant Regulations and Conditions, dated June 2011, as 
enclosed. Any changes to these will be advised and it is your responsibility and 
that of the Host Institution to take appropriate action to comply with these 
changes. 
Grant Holder(s): 
i) Principal Grant Holder: Dr Barry Laird 
ii) Co-Grant Holder(s): Dr Nicholas Macleod, Prof Anthony Chalmers, Dr 
Noelle O'Rourke, Prof Allan Price, Prof Marie Fallon, Dr F W Poon 
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Title of Research: An examination of [F-18]-fluoro-deoxy-glucose Positron 
Emission Tomography Computed Tomography (PET-CT) in radiotherapy 
planning and assessing treatment response in malignant pleural mesothelioma 
 
Type of Award:   Duration:   Amount 
awarded: 
Asbestos Pump-Priming Grant 16 months    £24,631 
Grant take-up 
Before the grant may be activated we must have received: 
i) The Acceptance Form attached to this letter signed by you as 
Principal Grant Holder and on behalf of: Dr Nicholas Macleod, Prof 
Anthony Chalmers, Dr Noelle O'Rourke, Prof Allan Price, Prof Marie 
Fallon, Dr F W Poon and Dr Kevin Blyth 
 ii) The Acceptance Form attached to the Award of Grant Letter 
dated 25 February 2016 which has been sent to your finance 
officer/bursar, signed on behalf of the Host Institution.  
 iii) If applicable, a copy of the written approval(s) from the 
Host Institution's Ethical Committee(s) and details of the 
relevant Home Office Licences – see paragraph 11 of the 
Regulations. 
You are asked to give the start date of the project on the Acceptance Form and 
your attention is drawn to paragraph 2 of the Regulations with regard to delays in 
starting your research.   
Claims for re-imbursement under the grant should be made by your finance 
officer/bursar in accordance with paragraph 5 of the Regulations, quoting the 
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grant reference number APP12-12. This reference number should be quoted in all 
correspondence relating to this grant.   
Finally, apart from funding research, the BLF is committed to providing 
information and support to people with lung disease and it is very important for 
our supporters to receive feedback about the research we are funding. I would 
therefore like to draw your attention particularly to paragraphs 13-16 of the 
Regulations. 




Head of Research 
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Appendix 4 – Ethics Approval and Consent Form 
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Appendix 5 - Questionnaires 
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Please go to the following website to access the CTCAE Version 
4.0.http://ctep.info.nih.gov/protocolDevelopment/electronic_applications/ctc.htm 
